FALSE 2022 Q2 AMEDISYS INC 0000896262--12-31 P5D P7D 9.7 17.3 1.8 1.8 Fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate for an interest period of one month plus 1% per annum.Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months 510,249 490,634 0000896262 2022-01-01 2022-06-30 0000896262 2022-07-22 xbrli:shares 0000896262 2022-06-30 iso4217:USD 0000896262 2021-12-31 iso4217:USD xbrli:shares 0000896262 2022-04-01 2022-06-30 0000896262 2021-04-01 2021-06-30 0000896262 2021-01-01 2021-06-30 0000896262 2022-03-31 0000896262 us-gaap:CommonStockMember 2022-03-31 0000896262 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000896262 us-gaap:TreasuryStockMember 2022-03-31 0000896262 us-gaap:RetainedEarningsMember 2022-03-31 0000896262 us-gaap:NoncontrollingInterestMember 2022-03-31 0000896262 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000896262 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000896262 us-gaap:TreasuryStockMember 2022-04-01 2022-06-30 0000896262 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0000896262 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000896262 us-gaap:CommonStockMember 2022-06-30 0000896262 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000896262 us-gaap:TreasuryStockMember 2022-06-30 0000896262 us-gaap:RetainedEarningsMember 2022-06-30 0000896262 us-gaap:NoncontrollingInterestMember 2022-06-30 0000896262 2021-03-31 0000896262 us-gaap:CommonStockMember 2021-03-31 0000896262 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000896262 us-gaap:TreasuryStockMember 2021-03-31 0000896262 us-gaap:RetainedEarningsMember 2021-03-31 0000896262 us-gaap:NoncontrollingInterestMember 2021-03-31 0000896262 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000896262 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000896262 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0000896262 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0000896262 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000896262 2021-06-30 0000896262 us-gaap:CommonStockMember 2021-06-30 0000896262 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000896262 us-gaap:TreasuryStockMember 2021-06-30 0000896262 us-gaap:RetainedEarningsMember 2021-06-30 0000896262 us-gaap:NoncontrollingInterestMember 2021-06-30 0000896262 us-gaap:CommonStockMember 2021-12-31 0000896262 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000896262 us-gaap:TreasuryStockMember 2021-12-31 0000896262 us-gaap:RetainedEarningsMember 2021-12-31 0000896262 us-gaap:NoncontrollingInterestMember 2021-12-31 0000896262 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0000896262 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0000896262 us-gaap:TreasuryStockMember 2022-01-01 2022-06-30 0000896262 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-06-30 0000896262 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0000896262 2020-12-31 0000896262 us-gaap:CommonStockMember 2020-12-31 0000896262 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000896262 us-gaap:TreasuryStockMember 2020-12-31 0000896262 us-gaap:RetainedEarningsMember 2020-12-31 0000896262 us-gaap:NoncontrollingInterestMember 2020-12-31 0000896262 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0000896262 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0000896262 us-gaap:TreasuryStockMember 2021-01-01 2021-06-30 0000896262 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-06-30 0000896262 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0000896262 us-gaap:RevenueFromContractWithCustomerMember amed:MedicareRevenueMember us-gaap:ProductConcentrationRiskMember 2022-04-01 2022-06-30 xbrli:pure 0000896262 us-gaap:RevenueFromContractWithCustomerMember amed:MedicareRevenueMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-06-30 0000896262 us-gaap:RevenueFromContractWithCustomerMember amed:MedicareRevenueMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-06-30 0000896262 us-gaap:RevenueFromContractWithCustomerMember amed:MedicareRevenueMember us-gaap:ProductConcentrationRiskMember 2021-04-01 2021-06-30 0000896262 amed:HomeHealthMember 2022-06-30 amed:care_center 0000896262 amed:HospiceMember 2022-06-30 0000896262 amed:PersonalCareMember 2022-06-30 0000896262 amed:HighAcuityCareMember 2022-06-30 amed:numberOfJointVentures amed:state 0000896262 amed:MedalogixMember 2021-01-01 2021-06-30 0000896262 2022-01-01 2022-03-31 0000896262 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2022-06-30 0000896262 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2021-12-31 0000896262 amed:HomeHealthMedicareMember 2022-04-01 2022-06-30 0000896262 amed:HomeHealthMedicareMember 2021-04-01 2021-06-30 0000896262 amed:HomeHealthMedicareMember 2022-01-01 2022-06-30 0000896262 amed:HomeHealthMedicareMember 2021-01-01 2021-06-30 0000896262 amed:HomeHealthNonMedicareEpisodicBasedMember 2022-04-01 2022-06-30 0000896262 amed:HomeHealthNonMedicareEpisodicBasedMember 2021-04-01 2021-06-30 0000896262 amed:HomeHealthNonMedicareEpisodicBasedMember 2022-01-01 2022-06-30 0000896262 amed:HomeHealthNonMedicareEpisodicBasedMember 2021-01-01 2021-06-30 0000896262 amed:HomeHealthNonMedicareNonEpisodicBasedMember 2022-04-01 2022-06-30 0000896262 amed:HomeHealthNonMedicareNonEpisodicBasedMember 2021-04-01 2021-06-30 0000896262 amed:HomeHealthNonMedicareNonEpisodicBasedMember 2022-01-01 2022-06-30 0000896262 amed:HomeHealthNonMedicareNonEpisodicBasedMember 2021-01-01 2021-06-30 0000896262 amed:HospiceMedicareMember 2022-04-01 2022-06-30 0000896262 amed:HospiceMedicareMember 2021-04-01 2021-06-30 0000896262 amed:HospiceMedicareMember 2022-01-01 2022-06-30 0000896262 amed:HospiceMedicareMember 2021-01-01 2021-06-30 0000896262 amed:HospiceNonMedicareMember 2022-04-01 2022-06-30 0000896262 amed:HospiceNonMedicareMember 2021-04-01 2021-06-30 0000896262 amed:HospiceNonMedicareMember 2022-01-01 2022-06-30 0000896262 amed:HospiceNonMedicareMember 2021-01-01 2021-06-30 0000896262 amed:PersonalCareMember 2022-04-01 2022-06-30 0000896262 amed:PersonalCareMember 2021-04-01 2021-06-30 0000896262 amed:PersonalCareMember 2022-01-01 2022-06-30 0000896262 amed:PersonalCareMember 2021-01-01 2021-06-30 0000896262 amed:HighAcuityCareMember 2022-04-01 2022-06-30 0000896262 amed:HighAcuityCareMember 2021-04-01 2021-06-30 0000896262 amed:HighAcuityCareMember 2022-01-01 2022-06-30 0000896262 amed:HighAcuityCareMember 2021-01-01 2021-06-30 0000896262 srt:MinimumMember amed:HomeHealthMember 2022-01-01 2022-06-30 amed:visit 0000896262 srt:MaximumMember amed:HomeHealthMember 2022-01-01 2022-06-30 0000896262 amed:HomeHealthMember 2022-01-01 2022-06-30 0000896262 amed:HospiceMember 2022-01-01 2022-06-30 0000896262 amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember 2022-06-30 0000896262 amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember 2021-12-31 0000896262 srt:MinimumMember amed:HighAcuityCareMember 2022-01-01 2022-06-30 0000896262 srt:MaximumMember amed:HighAcuityCareMember 2022-01-01 2022-06-30 0000896262 amed:VariousAcquisitionsMember 2022-06-30 0000896262 amed:VariousAcquisitionsMember 2021-12-31 0000896262 us-gaap:FairValueInputsLevel1Member 2022-06-30 0000896262 us-gaap:FairValueInputsLevel2Member 2022-06-30 0000896262 us-gaap:FairValueInputsLevel3Member 2022-06-30 0000896262 2020-03-27 0000896262 2020-04-01 2020-04-30 0000896262 us-gaap:EquityMethodInvestmentsMember 2020-04-01 2020-04-30 0000896262 amed:AseraCareHospiceMember 2020-04-01 2020-04-30 0000896262 2020-03-27 2021-06-30 0000896262 amed:COVID19DeferralOfSocialSecurityMember 2020-12-31 0000896262 amed:COVID19DeferralOfSocialSecurityMember 2021-01-01 2021-12-31 0000896262 amed:COVID19DeferralOfSocialSecurityMember 2022-06-30 0000896262 amed:A2022NewJointVentureMember 2022-03-23 2022-03-23 0000896262 amed:CertificateOfNeedAndLicensesMember amed:A2022NewJointVentureMember 2022-03-23 0000896262 amed:A2022NewJointVentureMember 2022-03-23 0000896262 amed:HomeHealthMember amed:EvolutionHealthMember 2022-04-01 2022-04-01 0000896262 amed:HomeHealthMember amed:EvolutionHealthMember 2022-06-30 0000896262 amed:HomeHealthMember amed:EvolutionHealthMember amed:PotentialClosingPaymentAdjustmentMember 2022-04-01 2022-04-01 0000896262 amed:HomeHealthMember amed:EvolutionHealthMember 2022-04-01 0000896262 amed:HomeHealthMember amed:EvolutionHealthMember 2022-01-01 2022-06-30 0000896262 amed:HomeHealthMember amed:EvolutionHealthMember 2022-04-01 2022-06-30 0000896262 amed:LicensesMember amed:HomeHealthMember amed:EvolutionHealthMember 2022-06-30 0000896262 amed:AssistedCareHomeHealthMember amed:HomeHealthMember 2022-04-01 2022-04-01 0000896262 amed:AssistedCareHomeHealthMember amed:HomeHealthMember 2022-06-30 0000896262 amed:AssistedCareHomeHealthMember amed:HomeHealthMember 2022-04-01 0000896262 amed:AssistedCareHomeHealthMember amed:LicensesMember amed:HomeHealthMember 2022-04-01 0000896262 amed:AssistedCareHomeHealthMember amed:CertificatesOfNeedMember amed:HomeHealthMember 2022-04-01 0000896262 amed:AssistedCareHomeHealthMember amed:AcquiredNamesMember amed:HomeHealthMember 2022-04-01 0000896262 amed:AssistedCareHomeHealthMember amed:AcquiredNamesMember amed:HomeHealthMember 2022-04-01 2022-04-01 0000896262 amed:AssistedCareHomeHealthMember amed:HomeHealthMember 2022-01-01 2022-06-30 0000896262 amed:AssistedCareHomeHealthMember amed:HomeHealthMember 2022-04-01 2022-06-30 0000896262 amed:ContessaHealthMember amed:HighAcuityCareMember 2021-08-01 2021-08-01 0000896262 amed:ContessaHealthMember amed:HighAcuityCareMember 2021-10-01 2021-12-31 0000896262 amed:ContessaHealthMember amed:HighAcuityCareMember 2022-06-30 0000896262 amed:ContessaHealthMember amed:HighAcuityCareMember 2022-04-01 2022-06-30 0000896262 amed:ContessaHealthMember amed:AcquiredNamesMember amed:HighAcuityCareMember 2021-08-01 0000896262 amed:ContessaHealthMember us-gaap:TechnologyBasedIntangibleAssetsMember amed:HighAcuityCareMember 2021-08-01 0000896262 amed:ContessaHealthMember amed:HighAcuityCareMember us-gaap:NoncompeteAgreementsMember 2021-08-01 0000896262 amed:ContessaHealthMember amed:HighAcuityCareMember us-gaap:NoncompeteAgreementsMember 2021-08-01 2021-08-01 0000896262 amed:ContessaHealthMember us-gaap:TechnologyBasedIntangibleAssetsMember amed:HighAcuityCareMember 2021-08-01 2021-08-01 0000896262 amed:ContessaHealthMember us-gaap:TechnologyBasedIntangibleAssetsMember amed:HighAcuityCareMember 2022-04-01 2022-06-30 0000896262 amed:ContessaHealthMember amed:HighAcuityCareMember 2022-01-01 2022-06-30 0000896262 amed:ContessaHealthMember us-gaap:TechnologyBasedIntangibleAssetsMember amed:HighAcuityCareMember 2022-01-01 2022-06-30 0000896262 us-gaap:LoansPayableMember amed:FourHundredFiftyMillionTermLoanFacilityMember 2022-06-30 0000896262 us-gaap:LoansPayableMember us-gaap:EurodollarMember amed:FourHundredFiftyMillionTermLoanFacilityMember 2022-06-30 0000896262 us-gaap:LoansPayableMember amed:FourHundredFiftyMillionTermLoanFacilityMember 2022-01-01 2022-06-30 0000896262 us-gaap:LoansPayableMember amed:FourHundredFiftyMillionTermLoanFacilityMember 2021-12-31 0000896262 us-gaap:RevolvingCreditFacilityMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2022-06-30 0000896262 us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2022-06-30 0000896262 us-gaap:RevolvingCreditFacilityMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2022-01-01 2022-06-30 0000896262 us-gaap:RevolvingCreditFacilityMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2021-12-31 0000896262 amed:PromissoryNotesMember 2022-06-30 0000896262 amed:PromissoryNotesMember 2021-12-31 0000896262 us-gaap:CapitalLeaseObligationsMember 2022-06-30 0000896262 us-gaap:CapitalLeaseObligationsMember 2021-12-31 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember 2021-07-30 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2021-07-30 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember amed:FourHundredFiftyMillionTermLoanFacilityMember 2021-07-30 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember 2021-07-30 2021-07-30 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember us-gaap:BaseRateMember 2022-01-01 2022-06-30 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember us-gaap:EurodollarMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember srt:MinimumMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember us-gaap:BaseRateMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember us-gaap:EurodollarMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember srt:MaximumMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember srt:MinimumMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember us-gaap:BaseRateMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember us-gaap:EurodollarMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember srt:MaximumMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember srt:MinimumMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember us-gaap:BaseRateMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember us-gaap:EurodollarMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember 2022-01-01 2022-06-30 0000896262 srt:MaximumMember amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember 2022-01-01 2022-06-30 0000896262 us-gaap:BaseRateMember amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember 2022-01-01 2022-06-30 0000896262 us-gaap:EurodollarMember amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember 2022-01-01 2022-06-30 0000896262 amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember 2022-01-01 2022-06-30 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember us-gaap:SubsequentEventMember 2021-07-30 2026-07-30 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember us-gaap:SubsequentEventMember amed:FourHundredFiftyMillionTermLoanFacilityMember 2021-07-30 2023-09-30 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember us-gaap:SubsequentEventMember amed:FourHundredFiftyMillionTermLoanFacilityMember 2023-10-01 2026-07-30 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember srt:MinimumMember 2021-07-30 2021-07-30 0000896262 us-gaap:RevolvingCreditFacilityMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2022-04-01 2022-06-30 0000896262 us-gaap:RevolvingCreditFacilityMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2021-04-01 2021-06-30 0000896262 us-gaap:RevolvingCreditFacilityMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2021-01-01 2021-06-30 0000896262 us-gaap:LoansPayableMember amed:FourHundredFiftyMillionTermLoanFacilityMember 2022-04-01 2022-06-30 0000896262 us-gaap:LoansPayableMember amed:FourHundredFiftyMillionTermLoanFacilityMember 2021-04-01 2021-06-30 0000896262 us-gaap:LoansPayableMember amed:FourHundredFiftyMillionTermLoanFacilityMember 2021-01-01 2021-06-30 0000896262 us-gaap:LineOfCreditMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2022-06-30 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember us-gaap:BaseRateMember 2021-07-30 2021-07-30 0000896262 amed:SecondAmendmentToAmendedCreditAgreementMember us-gaap:EurodollarMember 2021-07-30 2021-07-30 0000896262 amed:UsDepartmentOfJusticeMember amed:HospiceMember 2021-03-31 0000896262 amed:UsDepartmentOfJusticeMember amed:HospiceMember 2021-06-30 0000896262 amed:UsDepartmentOfJusticeMember amed:HospiceMember stpr:MA 2015-05-21 2015-05-21 amed:patient 0000896262 amed:UsDepartmentOfJusticeMember amed:HospiceMember amed:MorgantownWestVirginiaMember 2015-11-03 2015-11-03 0000896262 amed:UsDepartmentOfJusticeMember amed:ParkersburgWestVirginiaMember amed:HospiceMember 2016-06-27 2016-06-27 0000896262 stpr:SC amed:HospiceMember 2008-01-01 2010-03-31 amed:beneficiary 0000896262 amed:ExtrapolatedMember stpr:SC amed:HospiceMember 2011-06-06 2011-06-06 0000896262 amed:UnfavorableMember stpr:SC amed:HospiceMember 2016-01-18 0000896262 amed:UnfavorableMember stpr:SC amed:HospiceMember 2016-01-18 2016-01-18 amed:claim 0000896262 amed:UnfavorableMember stpr:SC amed:HospiceMember 2022-06-30 0000896262 stpr:SC amed:HospiceMember 2019-01-10 0000896262 stpr:SC amed:HospiceMember 2022-06-30 0000896262 amed:LakelandFloridaMember amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember 2017-08-31 0000896262 amed:LakelandFloridaMember amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember 2017-08-01 2017-08-31 0000896262 amed:ClearwaterFloridaMember amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember 2017-08-31 0000896262 amed:ClearwaterFloridaMember amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember 2017-08-01 2017-08-31 0000896262 amed:LakelandFloridaMember amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember 2022-06-30 0000896262 amed:ClearwaterFloridaMember amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember 2022-06-30 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember stpr:FL 2022-03-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember stpr:FL 2022-06-30 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember stpr:FL 2022-01-01 2022-06-30 0000896262 amed:InfinityHomeCareMember amed:SafeguardZoneProgramIntegrityContractorMember stpr:FL amed:HomeHealthMember 2022-06-30 amed:Segments 0000896262 amed:HomeHealthMember 2022-04-01 2022-06-30 0000896262 amed:HospiceMember 2022-04-01 2022-06-30 0000896262 amed:PersonalCareMember 2022-04-01 2022-06-30 0000896262 amed:HighAcuityCareMember 2022-04-01 2022-06-30 0000896262 us-gaap:AllOtherSegmentsMember 2022-04-01 2022-06-30 0000896262 amed:HomeHealthMember 2021-04-01 2021-06-30 0000896262 amed:HospiceMember 2021-04-01 2021-06-30 0000896262 amed:PersonalCareMember 2021-04-01 2021-06-30 0000896262 amed:HighAcuityCareMember 2021-04-01 2021-06-30 0000896262 us-gaap:AllOtherSegmentsMember 2021-04-01 2021-06-30 0000896262 amed:PersonalCareMember 2022-01-01 2022-06-30 0000896262 amed:HighAcuityCareMember 2022-01-01 2022-06-30 0000896262 us-gaap:AllOtherSegmentsMember 2022-01-01 2022-06-30 0000896262 amed:HomeHealthMember 2021-01-01 2021-06-30 0000896262 amed:HospiceMember 2021-01-01 2021-06-30 0000896262 amed:PersonalCareMember 2021-01-01 2021-06-30 0000896262 amed:HighAcuityCareMember 2021-01-01 2021-06-30 0000896262 us-gaap:AllOtherSegmentsMember 2021-01-01 2021-06-30 0000896262 amed:A2021ShareRepurchaseProgramMember 2020-12-23 0000896262 amed:A2021ShareRepurchaseProgramMember 2020-12-23 2021-12-31 0000896262 amed:A2021ShareRepurchaseProgramMember 2021-04-01 2021-06-30 0000896262 amed:A2021ShareRepurchaseProgramMember 2021-01-01 2021-06-30 0000896262 amed:NewShareRepurchaseProgramMember 2021-08-02 0000896262 us-gaap:SubsequentEventMember amed:NewShareRepurchaseProgramMember 2021-08-02 2022-12-31 0000896262 amed:NewShareRepurchaseProgramMember 2022-01-01 2022-06-30 0000896262 amed:NewShareRepurchaseProgramMember 2022-04-01 2022-06-30 0000896262 amed:MedalogixMember 2022-04-01 2022-06-30 0000896262 amed:MedalogixMember 2022-01-01 2022-06-30 0000896262 amed:MedalogixMember 2021-04-01 2021-06-30 0000896262 amed:MedalogixMember 2021-01-01 2021-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022
or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission File Number: 0-24260

AMEDISYS, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware |  | 11-3131700
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816
(Address of principal executive offices, including zip code)
(225) 292-2031 or (800) 467-2662
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, par value $0.001 per share |  | AMED |  | The NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer |  | ☒ |  | Accelerated filer |  | ☐
Non-accelerated filer |  | ☐ |  | Smaller reporting company |  | ☐
Emerging growth company |  | ☐ |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001 par value, 32,443,341 shares outstanding as of July 22, 2022.

TABLE OF CONTENTS

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS | 1
;;; |
PART I. | FINANCIAL INFORMATION |
ITEM 1. | FINANCIAL STATEMENTS: |
| CONDENSED CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2022 (UNAUDITED) AND DECEMBER 31, 2021 | 2
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED) | 3
| CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED) | 4
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX-MONTH PERIODS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED) | 5
ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 27
ITEM 3 | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 48
ITEM 4. | CONTROLS AND PROCEDURES | 48
PART II. OTHER INFORMATION |
ITEM 1. | LEGAL PROCEEDINGS | 49
ITEM 1A. | RISK FACTORS | 49
ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 49
ITEM 3. | DEFAULTS UPON SENIOR SECURITIES | 49
ITEM 4. | MINE SAFETY DISCLOSURES | 49
ITEM 5. | OTHER INFORMATION | 49
ITEM 6. | EXHIBITS | 50
SIGNATURES | 51

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS
When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (“SEC”) or in statements made by or on behalf of the Company, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; the impact of current and proposed federal, state and local vaccine mandates, including potential staffing shortages; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in Medicare and other medical payment levels; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; competition in the healthcare industry; changes in the case mix of patients and payment methodologies; changes in estimates and judgments associated with critical accounting policies; our ability to maintain or establish new patient referral sources; our ability to consistently provide high-quality care; our ability to attract and retain qualified personnel; our ability to keep our patients and employees safe; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest; our ability to integrate, manage and keep our information systems secure; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law. For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 24, 2022, particularly, Part I, Item 1A - Risk Factors therein, which are incorporated herein by reference, and Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.
Available Information
Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link “SEC filings”), free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link “Governance”). Reference to our website does not constitute incorporation by reference of the information contained on the website and should not be considered part of this document. Our electronically filed reports can also be obtained on the SEC’s internet site at http://www.sec.gov.
1

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)

| June 30, 2022 (Unaudited) |  | December 31, 2021
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 26,566 |  |  | $ | 42,694 |
Restricted cash | 22,198 |  |  | 3,075 |
Patient accounts receivable | 305,413 |  |  | 274,961 |
Prepaid expenses | 15,199 |  |  | 10,356 |
Other current assets | 25,493 |  |  | 25,598 |
Total current assets | 394,869 |  |  | 356,684 |
Property and equipment, net of accumulated depreciation of $100,265 and $96,937 | 17,847 |  |  | 18,435 |
Operating lease right of use assets | 107,723 |  |  | 101,257 |
Goodwill | 1,289,672 |  |  | 1,196,090 |
Intangible assets, net of accumulated amortization of $9,109 and $19,900 | 106,189 |  |  | 111,190 |
Deferred income tax assets | — |  |  | 289 |
Other assets | 84,686 |  |  | 73,023 |
Total assets | $ | 2,000,986 |  |  | $ | 1,856,968 |
LIABILITIES AND EQUITY |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 43,509 |  |  | $ | 38,217 |
Payroll and employee benefits | 161,068 |  |  | 141,001 |
Accrued expenses | 176,239 |  |  | 150,836 |
Current portion of long-term obligations | 12,521 |  |  | 12,995 |
Current portion of operating lease liabilities | 34,035 |  |  | 31,233 |
Total current liabilities | 427,372 |  |  | 374,282 |
Long-term obligations, less current portion | 442,413 |  |  | 432,075 |
Operating lease liabilities, less current portion | 72,619 |  |  | 69,309 |
Deferred income tax liabilities | 6,179 |  |  | — |
Other long-term obligations | 13,408 |  |  | 4,979 |
Total liabilities | 961,991 |  |  | 880,645 |
Commitments and Contingencies—Note 6 |  |  |
Equity: |  |  |
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding | — |  |  | — |
Common stock, $0.001 par value, 60,000,000 shares authorized; 37,780,242 and 37,674,868 shares issued; and 32,432,527 and 32,509,969 shares outstanding | 38 |  |  | 38 |
Additional paid-in capital | 743,276 |  |  | 728,118 |
Treasury stock, at cost 5,347,715 and 5,164,899 shares of common stock | (457,981) |  |  | (435,868) |
Retained earnings | 700,313 |  |  | 639,063 |
Total Amedisys, Inc. stockholders’ equity | 985,646 |  |  | 931,351 |
Noncontrolling interests | 53,349 |  |  | 44,972 |
Total equity | 1,038,995 |  |  | 976,323 |
Total liabilities and equity | $ | 2,000,986 |  |  | $ | 1,856,968 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
2

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except per share data)
(Unaudited)

| For the Three-Month Periods Ended June 30, |  | For the Six-Month Periods Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Net service revenue | $ | 557,890 |  |  | $ | 564,166 |  |  | $ | 1,103,147 |  |  | $ | 1,101,310 |
Other operating income | — |  |  | 4,603 |  |  | — |  |  | 13,304 |
Cost of service, excluding depreciation and amortization | 316,211 |  |  | 308,691 |  |  | 621,031 |  |  | 605,894 |
General and administrative expenses: |  |  |  |  |  |  |
Salaries and benefits | 127,758 |  |  | 114,335 |  |  | 251,238 |  |  | 230,160 |
Non-cash compensation | 5,148 |  |  | 6,156 |  |  | 12,495 |  |  | 13,463 |
Other | 54,912 |  |  | 54,731 |  |  | 108,552 |  |  | 103,837 |
Depreciation and amortization | 6,220 |  |  | 6,721 |  |  | 14,228 |  |  | 14,276 |
Operating expenses | 510,249 |  |  | 490,634 |  |  | 1,007,544 |  |  | 967,630 |
Operating income | 47,641 |  |  | 78,135 |  |  | 95,603 |  |  | 146,984 |
Other income (expense): |  |  |  |  |  |  |
Interest income | 36 |  |  | 25 |  |  | 49 |  |  | 49 |
Interest expense | (8,311) |  |  | (1,932) |  |  | (11,484) |  |  | (4,004) |
Equity in earnings (loss) from equity method investments | 659 |  |  | 1,370 |  |  | (744) |  |  | 2,488 |
Gain on equity method investments | — |  |  | 31,092 |  |  | — |  |  | 31,092 |
Miscellaneous, net | 331 |  |  | 475 |  |  | 664 |  |  | 763 |
Total other (expense) income, net | (7,285) |  |  | 31,030 |  |  | (11,515) |  |  | 30,388 |
Income before income taxes | 40,356 |  |  | 109,165 |  |  | 84,088 |  |  | 177,372 |
Income tax expense | (11,319) |  |  | (28,546) |  |  | (23,338) |  |  | (46,461) |
Net income | 29,037 |  |  | 80,619 |  |  | 60,750 |  |  | 130,911 |
Net loss (income) attributable to noncontrolling interests | 542 |  |  | (470) |  |  | 500 |  |  | (892) |
Net income attributable to Amedisys, Inc. | $ | 29,579 |  |  | $ | 80,149 |  |  | $ | 61,250 |  |  | $ | 130,019 |
Basic earnings per common share: |  |  |  |  |  |  |
Net income attributable to Amedisys, Inc. common stockholders | $ | 0.91 |  |  | $ | 2.46 |  |  | $ | 1.88 |  |  | $ | 3.98 |
Weighted average shares outstanding | 32,522 |  |  | 32,588 |  |  | 32,538 |  |  | 32,684 |
Diluted earnings per common share: |  |  |  |  |  |  |
Net income attributable to Amedisys, Inc. common stockholders | $ | 0.91 |  |  | $ | 2.43 |  |  | $ | 1.87 |  |  | $ | 3.93 |
Weighted average shares outstanding | 32,681 |  |  | 32,981 |  |  | 32,722 |  |  | 33,085 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
3

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Amounts in thousands, except common stock shares)
(Unaudited)

| For the Three-Months Ended June 30, 2022
| Total |  | Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Retained Earnings |  | Noncontrolling Interests
Shares |  | Amount |
Balance, March 31, 2022 | $ | 1,020,652 |  |  | 37,763,705 |  |  | $ | 38 |  |  | $ | 736,536 |  |  | $ | (440,550) |  |  | $ | 670,734 |  |  | $ | 53,894 |
Issuance of stock – employee stock purchase plan | 906 |  |  | 6,184 |  |  | — |  |  | 906 |  |  | — |  |  | — |  |  | — |
Issuance/(cancellation) of non-vested stock | — |  |  | 3,812 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Exercise of stock options | 686 |  |  | 6,541 |  |  | — |  |  | 686 |  |  | — |  |  | — |  |  | — |
Non-cash compensation | 5,148 |  |  | — |  |  | — |  |  | 5,148 |  |  | — |  |  | — |  |  | — |
Surrendered shares | (80) |  |  | — |  |  | — |  |  | — |  |  | (80) |  |  | — |  |  | — |
Shares repurchased | (17,351) |  |  | — |  |  | — |  |  | — |  |  | (17,351) |  |  | — |  |  | — |
Noncontrolling interest contributions | 300 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 300 |
Noncontrolling interest distributions | (303) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (303) |
Net income (loss) | 29,037 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 29,579 |  |  | (542) |
Balance, June 30, 2022 | $ | 1,038,995 |  |  | 37,780,242 |  |  | $ | 38 |  |  | $ | 743,276 |  |  | $ | (457,981) |  |  | $ | 700,313 |  |  | $ | 53,349 |
| For the Three-Months Ended June 30, 2021
| Total |  | Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Retained Earnings |  | Noncontrolling Interests
Shares |  | Amount |
Balance, March 31, 2021 | $ | 789,574 |  |  | 37,538,837 |  |  | $ | 38 |  |  | $ | 707,006 |  |  | $ | (398,752) |  |  | $ | 479,861 |  |  | $ | 1,421 |
Issuance of stock – employee stock purchase plan | 913 |  |  | 4,060 |  |  | — |  |  | 913 |  |  | — |  |  | — |  |  | — |
Issuance/(cancellation) of non-vested stock | — |  |  | 4,068 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Exercise of stock options | 259 |  |  | 6,390 |  |  | — |  |  | 259 |  |  | — |  |  | — |  |  | — |
Non-cash compensation | 6,156 |  |  | — |  |  | — |  |  | 6,156 |  |  | — |  |  | — |  |  | — |
Surrendered shares | (170) |  |  | — |  |  | — |  |  | — |  |  | (170) |  |  | — |  |  | — |
Shares repurchased | (1,188) |  |  | — |  |  | — |  |  | — |  |  | (1,188) |  |  | — |  |  | — |
Noncontrolling interest distributions | (276) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (276) |
Net income | 80,619 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 80,149 |  |  | 470 |
Balance, June 30, 2021 | $ | 875,887 |  |  | 37,553,355 |  |  | $ | 38 |  |  | $ | 714,334 |  |  | $ | (400,110) |  |  | $ | 560,010 |  |  | $ | 1,615 |
| For the Six-Months Ended June 30, 2022
| Total |  | Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Retained Earnings |  | Noncontrolling Interests
Shares |  | Amount |
Balance, December 31, 2021 | $ | 976,323 |  |  | 37,674,868 |  |  | $ | 38 |  |  | $ | 728,118 |  |  | $ | (435,868) |  |  | $ | 639,063 |  |  | $ | 44,972 |
Issuance of stock – employee stock purchase plan | 1,891 |  |  | 13,345 |  |  | — |  |  | 1,891 |  |  | — |  |  | — |  |  | — |
Issuance/(cancellation) of non-vested stock | — |  |  | 84,306 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Exercise of stock options | 772 |  |  | 7,723 |  |  | — |  |  | 772 |  |  | — |  |  | — |  |  | — |
Non-cash compensation | 12,495 |  |  | — |  |  | — |  |  | 12,495 |  |  | — |  |  | — |  |  | — |
Surrendered shares | (4,762) |  |  | — |  |  | — |  |  | — |  |  | (4,762) |  |  | — |  |  | — |
Shares repurchased | (17,351) |  |  | — |  |  | — |  |  | — |  |  | (17,351) |  |  | — |  |  | — |
Noncontrolling interest contributions | 9,852 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 9,852 |
Noncontrolling interest distributions | (975) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (975) |
Net income (loss) | 60,750 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 61,250 |  |  | (500) |
Balance, June 30, 2022 | $ | 1,038,995 |  |  | 37,780,242 |  |  | $ | 38 |  |  | $ | 743,276 |  |  | $ | (457,981) |  |  | $ | 700,313 |  |  | $ | 53,349 |
| For the Six-Months Ended June 30, 2021
| Total |  | Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Retained Earnings |  | Noncontrolling Interests
Shares |  | Amount |
Balance, December 31, 2020 | $ | 810,741 |  |  | 37,470,212 |  |  | $ | 38 |  |  | $ | 698,287 |  |  | $ | (319,092) |  |  | $ | 429,991 |  |  | $ | 1,517 |
Issuance of stock – employee stock purchase plan | 1,961 |  |  | 8,262 |  |  | — |  |  | 1,961 |  |  | — |  |  | — |  |  | — |
Issuance/(cancellation) of non-vested stock | — |  |  | 61,069 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Exercise of stock options | 623 |  |  | 13,812 |  |  | — |  |  | 623 |  |  | — |  |  | — |  |  | — |
Non-cash compensation | 13,463 |  |  | — |  |  | — |  |  | 13,463 |  |  | — |  |  | — |  |  | — |
Surrendered shares | (6,944) |  |  | — |  |  | — |  |  | — |  |  | (6,944) |  |  | — |  |  | — |
Shares repurchased | (74,074) |  |  | — |  |  | — |  |  | — |  |  | (74,074) |  |  | — |  |  | — |
Noncontrolling interest distributions | (794) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (794) |
Net income | 130,911 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 130,019 |  |  | 892 |
Balance, June 30, 2021 | $ | 875,887 |  |  | 37,553,355 |  |  | $ | 38 |  |  | $ | 714,334 |  |  | $ | (400,110) |  |  | $ | 560,010 |  |  | $ | 1,615 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
4

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
(Unaudited)

| For the Six-Month Periods Ended June 30,
| 2022 |  | 2021
Cash Flows from Operating Activities: |  |  |
Net income | $ | 60,750 |  |  | $ | 130,911 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
Depreciation and amortization | 14,228 |  |  | 14,276 |
Non-cash compensation | 12,495 |  |  | 13,463 |
Amortization and impairment of operating lease right of use assets | 22,463 |  |  | 19,702 |
Loss on disposal of property and equipment | 531 |  |  | 8 |
Gain on equity method investments | — |  |  | (31,092) |
Deferred income taxes | 6,003 |  |  | 22,716 |
Equity in loss (earnings) from equity method investments | 744 |  |  | (2,488) |
Amortization of deferred debt issuance costs/debt discount | 495 |  |  | 432 |
Return on equity method investments | 2,428 |  |  | 2,683 |
Changes in operating assets and liabilities, net of impact of acquisitions: |  |  |
Patient accounts receivable | (21,344) |  |  | (22,787) |
Other current assets | (4,468) |  |  | 3,560 |
Other assets | 220 |  |  | (52) |
Accounts payable | 4,498 |  |  | (6,530) |
Accrued expenses | 29,529 |  |  | (1,627) |
Other long-term obligations | (223) |  |  | (1,736) |
Operating lease liabilities | (20,657) |  |  | (17,955) |
Operating lease right of use assets | (1,662) |  |  | (1,524) |
Net cash provided by operating activities | 106,030 |  |  | 121,960 |
Cash Flows from Investing Activities: |  |  |
Proceeds from the sale of deferred compensation plan assets | 28 |  |  | 25 |
Proceeds from the sale of property and equipment | 37 |  |  | 42 |
Purchases of property and equipment | (2,782) |  |  | (2,943) |
Investments in technology assets | (559) |  |  | — |
Other investments | (15,000) |  |  | — |
Acquisitions of businesses, net of cash acquired | (73,311) |  |  | (2,503) |
Net cash used in investing activities | (91,587) |  |  | (5,379) |
Cash Flows from Financing Activities: |  |  |
Proceeds from issuance of stock upon exercise of stock options | 772 |  |  | 623 |
Proceeds from issuance of stock to employee stock purchase plan | 1,891 |  |  | 1,961 |
Shares withheld to pay taxes on non-cash compensation | (4,762) |  |  | (6,944) |
Noncontrolling interest contributions | 952 |  |  | — |
Noncontrolling interest distributions | (975) |  |  | (794) |
Proceeds from borrowings under revolving line of credit | 298,500 |  |  | 389,200 |
Repayments of borrowings under revolving line of credit | (283,500) |  |  | (410,200) |
Principal payments of long-term obligations | (6,975) |  |  | (5,392) |
Purchase of company stock | (17,351) |  |  | (74,074) |
Provider relief fund advance | — |  |  | (1,672) |
Net cash used in financing activities | (11,448) |  |  | (107,292) |
Net increase in cash, cash equivalents and restricted cash | 2,995 |  |  | 9,289 |
Cash, cash equivalents and restricted cash at beginning of period | 45,769 |  |  | 83,357 |
Cash, cash equivalents and restricted cash at end of period | $ | 48,764 |  |  | $ | 92,646 |

5

Supplemental Disclosures of Cash Flow Information: |  |  |
Cash paid for interest | $ | 4,489 |  |  | $ | 1,914 |
Cash paid for income taxes, net of refunds received | $ | 22,977 |  |  | $ | 8,667 |
Cash paid for operating lease liabilities | $ | 22,319 |  |  | $ | 19,479 |
Cash paid for finance lease liabilities | $ | 735 |  |  | $ | 1,017 |
Supplemental Disclosures of Non-Cash Activity: |  |  |
Right of use assets obtained in exchange for operating lease liabilities | $ | 26,590 |  |  | $ | 20,689 |
Right of use assets obtained in exchange for finance lease liabilities | $ | 1,316 |  |  | $ | 527 |
Reductions to right of use assets resulting from reductions to operating lease liabilities | $ | 2,763 |  |  | $ | 904 |
Accrued contingent consideration | $ | 19,195 |  |  | $ | — |
Noncontrolling interest contribution | $ | 8,900 |  |  | $ | — |

The accompanying notes are an integral part of these condensed consolidated financial statements.
6

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS
Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as “Amedisys,” “we,” “us,” or “our”), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately 74% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2022 and approximately 75% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2021. As of June 30, 2022, we owned and operated 353 Medicare-certified home health care centers, 174 Medicare-certified hospice care centers, 14 personal-care care centers and 9 admitting high acuity care joint ventures in 38 states within the United States and the District of Columbia.
Basis of Presentation
In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.
This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (“SEC”) on February 24, 2022 (the “Form 10-K”), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations.
Use of Estimates
Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Principles of Consolidation
These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.
Investments
We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.
We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $45.0 million and $48.1 million as of June 30, 2022 and December 31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets.
During 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1 million gain based on the purchase price of Medalogix during the three-month period ended June 30, 2021, which is reflected in gain on equity method investments within our condensed consolidated statements of operations.
7

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During the three-month period ended March 31, 2022, we made a $15.0 million investment in an entity accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0 million and $5.0 million as of June 30, 2022 and December 31, 2021, respectively, and is reflected in other assets within our condensed consolidated balance sheets.
Our high acuity care segment includes interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of June 30, 2022, we are consolidating all but one of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time, we may be required to provide joint venture funding. We account for one of our admitting joint ventures with health system partners under the equity method of accounting as we are not considered to be the primary beneficiary of this VIE.
The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs’ assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):

| As of June 30, 2022 |  | As of December 31, 2021
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 10.4 |  |  | $ | 3.1 |
Patient accounts receivable | 4.1 |  |  | 2.4 |
Other current assets | 0.4 |  |  | 0.1 |
Total current assets | 14.9 |  |  | 5.6 |
Property and equipment | 0.2 |  |  | 0.1 |
Goodwill | 8.5 |  |  | — |
Intangible assets | 0.4 |  |  | — |
Total assets | $ | 24.0 |  |  | $ | 5.7 |
LIABILITIES |  |  |
Current liabilities: |  |  |
Payroll and employee benefits | $ | 0.7 |  |  | $ | 0.3 |
Accrued expenses | 4.8 |  |  | 3.4 |
Current portion of long-term obligations | 0.2 |  |  | 0.8 |
Total current liabilities | 5.7 |  |  | 4.5 |
Other long-term obligations | — |  |  | — |
Total liabilities | $ | 5.7 |  |  | $ | 4.5 |

8

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Revenue Recognition
We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material.
Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.
Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.
We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change.
Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represented approximately 74% of our consolidated net service revenue for the three and six-month periods ended June 30, 2022 and approximately 75% of our consolidated net service revenue for the three and six-month periods ended June 30, 2021.
Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.
We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.
9

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Revenue by payor class as a percentage of total net service revenue is as follows:

| For the Three-Month Periods Ended June 30, |  | For the Six-Month Periods Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Home Health: |  |  |  |  |  |  |
Medicare | 40 | % |  | 42 | % |  | 40 | % |  | 42 | %
Non-Medicare - Episodic-based | 8 | % |  | 8 | % |  | 8 | % |  | 8 | %
Non-Medicare - Non-episodic based | 13 | % |  | 12 | % |  | 12 | % |  | 12 | %
Hospice: |  |  |  |  |  |  |
Medicare | 33 | % |  | 33 | % |  | 34 | % |  | 33 | %
Non-Medicare | 2 | % |  | 2 | % |  | 2 | % |  | 2 | %
Personal Care | 3 | % |  | 3 | % |  | 3 | % |  | 3 | %
High Acuity Care (1) | 1 | % |  | — | % |  | 1 | % |  | — | %
| 100 | % |  | 100 | % |  | 100 | % |  | 100 | %

(1) Acquired Contessa Health on August 1, 2021.
Home Health Revenue Recognition
Medicare Revenue
Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.
All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day periods of care.
Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity’s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day period of care. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.
PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b) a low utilization payment adjustment (“LUPA”) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c) a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.
Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.
Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.
10

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit.
Non-Medicare Revenue
Episodic-based Revenue. We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.
Non-episodic based Revenue. Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.
Hospice Revenue Recognition
Hospice Medicare Revenue
Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and six-month periods ended June 30, 2022 and June 30, 2021. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (“SIA”). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.
The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.
We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.
Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded. We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28 th of the following year. Effective with the 2016 final rule, the cap year was changed to align with the federal fiscal year which begins on October 1st and ends on September 30th. As of June 30, 2022, we have recorded $4.2 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October 31, 2016 through September 30, 2022. As of December 31, 2021, we had recorded $4.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October 31, 2016 through September 30, 2022.
11

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Hospice Non-Medicare Revenue
Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.
Personal Care Revenue Recognition
Personal Care Revenue
We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA").
High Acuity Care Revenue Recognition
High Acuity Care Revenue
Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services.
Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians’ orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.
Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient’s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.
We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.
12

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.
Government Grants
We account for government grants in accordance with Accounting Standards Update ("ASU") 2021-10, Government Assistance (Topic 832), by applying the grant model in accordance with International Accounting Standard ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 – Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act").
Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of June 30, 2022 and December 31, 2021, we had $22.2 million and $3.1 million, respectively, of restricted cash that was placed into escrow accounts related to the indemnity, closing payment and various other provisions within the purchase agreements of our acquisitions. The increase in restricted cash from December 31, 2021 to June 30, 2022 is related to our acquisitions of Evolution Health, LLC ("Evolution") and AssistedCare Home Health, Inc. and RH Homecare Services, LLC ("AssistedCare") on April 1, 2022. See Note 4 – Acquisitions for additional information.
The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):

| As of June 30, 2022 |  | As of December 31, 2021
Cash and cash equivalents | $ | 26.6 |  |  | $ | 42.7 |
Restricted cash | 22.2 |  |  | 3.1 |
Cash, cash equivalents and restricted cash | $ | 48.8 |  |  | $ | 45.8 |

Patient Accounts Receivable
We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of June 30, 2022, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 68% of our patient accounts receivable at June 30, 2022 and December 31, 2021, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor.
We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.
13

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Medicare Home Health
For our home health patients (within both our home health and high acuity care segments), our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.
Medicare Hospice
For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.
Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care
For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient’s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.
Business Combinations
We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, Business Combinations. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.
14

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Fair Value of Financial Instruments
The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):

| Fair Value at Reporting Date Using
Financial Instrument | Carrying Value as of June 30, 2022 |  | Quoted Prices in Active Markets for Identical Items (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Long-term obligations | $ | 456.8 |  |  | $ | — |  |  | $ | 476.9 |  |  | $ | — |

The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:
•Level 1 – Quoted prices in active markets for identical assets and liabilities.
•Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.
Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.
Weighted-Average Shares Outstanding
Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):

| For the Three- Month Periods Ended June 30, |  | For the Six- Month Periods Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Weighted average number of shares outstanding - basic | 32,522 |  |  | 32,588 |  |  | 32,538 |  |  | 32,684 |
Effect of dilutive securities: |  |  |  |  |  |  |
Stock options | 46 |  |  | 139 |  |  | 56 |  |  | 145 |
Non-vested stock and stock units | 113 |  |  | 254 |  |  | 128 |  |  | 256 |
Weighted average number of shares outstanding - diluted | 32,681 |  |  | 32,981 |  |  | 32,722 |  |  | 33,085 |
Anti-dilutive securities | 283 |  |  | 71 |  |  | 250 |  |  | 58 |

15

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
3. NOVEL CORONAVIRUS PANDEMIC ("COVID-19")
In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.
On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $175 billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30 billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100 million from the first $30 billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2 million related to our joint venture care centers (equity method investments). We also acquired approximately $6 million of PRF funds in connection with the acquisition of AseraCare Hospice ("AseraCare"). Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021.
For our wholly-owned subsidiaries, we utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred through June 30, 2021 is reflected in other operating income within our condensed consolidated statements of operations.
We did not fully utilize the PRF funds received; all unutilized funds were repaid in October 2021. In summary, the total funds that we received from the CARES Act PRF were accounted for as follows (amounts in millions):

| Amount
Funds utilized through June 30, 2021 by consolidated entities | $ | 46.6 |
Funds repaid to the government by consolidated entities (excludes $0.2 million of interest repaid) | 58.3 |
Funds utilized through June 30, 2021 by unconsolidated joint ventures | 1.3 |
Funds repaid to the government by unconsolidated joint ventures | 0.6 |
| $ | 106.8 |

The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. In December 2021, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act. This legislation extended the 2% suspension of sequestration through March 31, 2022; sequestration was reinstated as a 1% reduction to Medicare claim reimbursements effective April 1, 2022 and has been reinstated as a 2% reduction to Medicare claim reimbursements effective July 1, 2022. The suspension of sequestration increased net service revenue by $4 million and $13 million during the three and six-month periods ended June 30, 2022, respectively, and $10 million and $18 million during the three and six-month periods ended June 30, 2021, respectively.
Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. During 2020, we deferred approximately $55 million of social security taxes. Approximately $27 million was paid during December 2021; the remaining balance is due on December 31, 2022 and is reflected in payroll and employee benefits within our condensed consolidated balance sheet.
16

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
4. ACQUISITIONS
We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm’s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.
2022 Acquisitions
On March 23, 2022, we entered into a transaction with one of our high acuity care health system partners in which we contributed cash and our health system partner contributed its home health operations to one of our existing high acuity care joint ventures. As a result of this transaction, we recorded goodwill of $8.5 million, other intangibles of $0.4 million (certificate of need and licenses) and noncontrolling interest of $8.9 million within our condensed consolidated balance sheet. The fair value of noncontrolling interest was determined using an income approach and a market approach.
On April 1, 2022, we acquired 15 home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution"), for an estimated purchase price of $67.8 million. A portion of the purchase price ($51.1 million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($16.7 million) was placed into an escrow account in accordance with the closing payment, indemnity and other provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. Corresponding liabilities were also recorded to accrued expenses and other long-term obligations within our condensed consolidated balance sheet related to these contingent consideration arrangements.
Of the total $16.7 million placed into escrow, $1.0 million has been set aside for any potential closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price is subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. We expect to finalize any changes to the purchase price resulting from the closing payment adjustment during the three-month period ending September 30, 2022. The remaining $15.7 million placed into escrow relates to certain outstanding matters existing as of the acquisition date as well as potential losses the Company may incur for which the seller has an obligation to indemnify the Company. This amount will either be paid to third parties as outstanding matters are resolved or to the seller at certain intervals in the future.
We expect $15 million of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.
Evolution contributed $11.3 million in net service revenue and an operating loss of $1.8 million during the three and six-month periods ended June 30, 2022.
The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of $67.8 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):
17

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

| Amount
ASSETS |
Patient accounts receivable | $ | 9.1 |
Prepaid expenses | 0.2 |
Other current assets | 0.1 |
Property and equipment | 2.5 |
Operating lease right of use assets | 3.2 |
Intangible assets (licenses) | 1.3 |
Other assets | 0.1 |
Total assets acquired | $ | 16.5 |
LIABILITIES AND EQUITY |
Accounts payable | $ | (0.7) |
Payroll and employee benefits | (2.7) |
Accrued expenses | (2.4) |
Operating lease liabilities | (2.8) |
Deferred income tax liability | (0.5) |
Current portion of long-term obligations | (0.6) |
Total liabilities assumed | (9.7) |
Net identifiable assets acquired | $ | 6.8 |
Goodwill | 61.0 |
Total consideration | $ | 67.8 |

On April 1, 2022, we acquired two home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $24.7 million. A portion of the purchase price ($22.2 million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($2.5 million) was placed into an escrow account in accordance with the indemnity provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. A corresponding liability was also recorded to other long-term obligations within our condensed consolidated balance sheet related to this contingent consideration arrangement. The $2.5 million will either be paid to third parties or to the seller at certain intervals in the future.
Based on the Company's preliminary valuation, we recorded goodwill of $24.0 million and other intangibles of $0.7 million in connection with the acquisition. Intangible assets acquired include licenses ($0.5 million), certificates of need ($0.2 million) and acquired names ($0.1 million). The acquired names will be amortized over a weighted average period of one year.
We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.
AssistedCare contributed $2.6 million in net service revenue and operating income of $0.7 million during the three and six-month periods ended June 30, 2022.
2021 Acquisitions
On August 1, 2021, we acquired Contessa, a leader in hospital-at-home and skilled nursing facility at-home services for an estimated purchase price of $240.7 million, net of cash acquired. The Contessa purchase price included estimates for cash, working capital and other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended December 31, 2021, increased the purchase price by $0.6 million from $240.7 million to $241.3 million.
18

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The Company is in the process of reviewing the fair value of the assets acquired, liabilities assumed and noncontrolling interests. Based on the Company's preliminary valuation, which may be revised as additional information becomes available during the measurement period, the total estimated consideration of $241.3 million has been allocated to assets acquired, liabilities assumed and noncontrolling interests as of the acquisition date as follows (amounts in millions):

| Amount
ASSETS |
Patient accounts receivable | $ | 1.5 |
Prepaid expenses | 0.3 |
Other current assets | 0.1 |
Property and equipment | 0.3 |
Operating lease right of use assets | 0.8 |
Intangible assets | 54.3 |
Other assets | 3.1 |
Total assets acquired | $ | 60.4 |
LIABILITIES AND EQUITY |
Accounts payable | $ | (0.1) |
Payroll and employee benefits | (0.6) |
Accrued expenses | (3.4) |
Operating lease liabilities | (0.8) |
Deferred income tax liability | (3.1) |
Current portion of long-term obligations | (0.9) |
Other long-term obligations | (0.2) |
Total liabilities assumed | (9.1) |
Noncontrolling interests | (43.9) |
Total equity assumed | (43.9) |
Total liabilities and equity assumed | $ | (53.0) |
Net identifiable assets acquired | $ | 7.4 |
Goodwill | 233.9 |
Total consideration | $ | 241.3 |

Intangible assets acquired include acquired names ($28.3 million), technology ($19.8 million) and non-compete agreements ($6.2 million). The non-compete agreements will be amortized over a weighted-average period of 2.0 years, and the technology will be amortized over a weighted-average period of 7.0 years. The fair value of noncontrolling interest ($43.9 million) was determined using an income approach.
We do not expect any of the goodwill recorded for this acquisition to be deductible for income tax purposes.
Contessa contributed $4.4 million in net service revenue and an operating loss of $9.7 million (inclusive of technology intangibles amortization totaling $0.7 million) during the three-month period ended June 30, 2022 and $7.2 million in net service revenue and an operating loss of $17.3 million (inclusive of technology intangibles amortization totaling $1.5 million) during the six-month period ended June 30, 2022.
For details regarding the Company's 2021 acquisitions, see Note 4 to the audited consolidated financial statements in our 2021 Annual Report on Form 10-K.
19

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
5. LONG-TERM OBLIGATIONS
Long-term debt consists of the following for the periods indicated (amounts in millions):

| June 30, 2022 |  | December 31, 2021
$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.2% at June 30, 2022); due July 30, 2026 | $ | 441.6 |  |  | $ | 447.2 |
$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.7% at June 30, 2022); due July 30, 2026 | 15.0 |  |  | — |
Promissory notes | 0.2 |  |  | 0.8 |
Finance leases | 2.2 |  |  | 1.6 |
Principal amount of long-term obligations | 459.0 |  |  | 449.6 |
Deferred debt issuance costs | (4.1) |  |  | (4.5) |
| 454.9 |  |  | 445.1 |
Current portion of long-term obligations | (12.5) |  |  | (13.0) |
Total | $ | 442.4 |  |  | $ | 432.1 |

Second Amendment to the Credit Agreement
On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0 billion, which includes a $550.0 million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0 million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").
Net proceeds from the $450.0 million Amended Term Loan Facility were used to fund the Contessa acquisition.
The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The “Base Rate” means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus 1% per annum. The “Eurodollar Rate” means the quoted rate per annum equal to the London Interbank Offered Rate (“LIBOR”) or a comparable successor rate approved by the Administrative Agent for an interest period of one, three or six months (as selected by us). The “Applicable Rate” is based on the consolidated leverage ratio and is presented in the table below. As of June 30, 2022, the Applicable Rate is 0.50% per annum for Base Rate loans and 1.50% per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.

Pricing Tier | Consolidated Leverage Ratio | Base Rate Loans | Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans | Commitment Fee | Letter of Credit Fee
I | > 3.00 to 1.0 | 1.00% | 2.00% | 0.30% | 1.75%
II | < 3.00 to 1.0 but > 2.00 to 1.0 | 0.75% | 1.75% | 0.25% | 1.50%
III | < 2.00 to 1.0 but > 0.75 to 1.0 | 0.50% | 1.50% | 0.20% | 1.25%
IV | < 0.75 to 1.0 | 0.25% | 1.25% | 0.15% | 1.00%

The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any
20

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5 million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.
The Second Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Second Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Second Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Second Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Second Amended Credit Agreement.
The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Second Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.
Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 2.9% for the three and six-month periods ended June 30, 2022, and 1.7% and 1.8% for the three and six-month periods ended June 30, 2021, respectively. Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 2.3% and 2.0% for the three and six-month periods ended June 30, 2022, respectively, and 1.4% and 1.5% for the three and six-month periods ended June 30, 2021, respectively.
As of June 30, 2022, our consolidated leverage ratio was 1.7, our consolidated interest coverage ratio was 15.4 and we are in compliance with our covenants under the Second Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.
As of June 30, 2022, our availability under our $550.0 million Revolving Credit Facility was $507.3 million as we have $15.0 million outstanding in borrowings and $27.7 million outstanding in letters of credit.
Joinder Agreements
In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the “CCH Joinder”), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the “Amended and Restated Security Agreement”), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the “Amended and Restated Pledge Agreement”). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the “AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana Hospice ("Asana"), which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the “Contessa and Asana Joinder,” and together with the CCH Joinder and the AseraCare Joinder, the “Joinders”).
21

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Second Amended Credit Agreement pursuant to the terms of the Joinders and the Second Amended Credit Agreement.
6. COMMITMENTS AND CONTINGENCIES
Legal Proceedings - Ongoing
We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.
Legal fees related to all legal matters are expensed as incurred.
Legal Proceedings - Completed
Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice
On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). At the time, we had $6.5 million recorded to accrued expenses in our condensed consolidated balance sheets related to these matters. We reversed this accrual during the three-month period ended June 30, 2021.
On May 21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding 53 identified hospice patients to the United States Attorney’s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January 1, 2011 through May 21, 2015.
On November 3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney’s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January 1, 2009 through August 31, 2015.
On June 27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney’s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January 1, 2011 through June 20, 2016.
Third Party Audits - Ongoing
From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (“RACs”), Zone Program Integrity Contractors (“ZPICs”), Uniform Program Integrity Contractors (“UPICs”), Program Safeguard Contractors (“PSCs”), Medicaid Integrity Contractors (“MICs”), Supplemental Medical Review Contractors (“SMRCs”) and the Office of the Inspector General (“OIG”), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.
22

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January 1, 2008 through March 31, 2010 (the “Review Period”) to determine whether the underlying services met pertinent Medicare payment requirements. We acquired the hospice operations subject to this review on August 1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations. Based on the ZPIC’s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June 6, 2011, the Medicare Administrative Contractor (“MAC”) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January 18, 2016, we received a letter dated January 6, 2016 referencing the ALJ hearing decision for the overpayment issued on June 6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid. No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of June 30, 2022, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August 1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.
In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (“SafeGuard”), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an extrapolated overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an extrapolated overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.
The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center was reduced to $3.3 million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022.
The Company received the results of the ALJ hearing for the Clearwater Care Center and the Lakeland Care Centers on June 23, 2022 and June 30, 2022, respectively. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As of the date of this filing, we do not have a demand for repayment from Palmetto for the Clearwater Care Center or the Lakeland Care Centers.
At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing of the demand for repayment; however, the Company has updated its estimates of potential loss based on the ALJ's decisions. We have increased our total accrual related to these matters from $17.4 million to $25.8 million. The net of these two amounts, $8.4 million, was recorded as a reduction to net service revenue in our condensed consolidated statements of operations during the three-month period ended June 30, 2022. We expect to be indemnified by the prior owners for approximately $10.9 million and have recorded this amount within other assets in our condensed consolidated balance sheets. As of June 30, 2022, $1.5 million of receivables have been impacted by these matters.
23

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Insurance
We are obligated for certain costs associated with our insurance programs, including employee health, workers’ compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.
Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers’ compensation insurance has a retention limit of $2.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident.
7. SEGMENT INFORMATION
Our operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa on August 1, 2021, delivers the essential elements of inpatient hospital and SNF care to patients in their homes. The “other” column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.
24

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company’s chief operating decision maker and therefore are not disclosed below (amounts in millions).

| For the Three-Month Period Ended June 30, 2022
| Home Health |  | Hospice |  | Personal Care |  | High Acuity Care |  | Other |  | Total
Net service revenue | $ | 340.2 |  |  | $ | 198.4 |  |  | $ | 14.9 |  |  | $ | 4.4 |  |  | $ | — |  |  | $ | 557.9 |
Cost of service, excluding depreciation and amortization | 193.0 |  |  | 107.4 |  |  | 11.4 |  |  | 4.4 |  |  | — |  |  | 316.2 |
General and administrative expenses | 87.9 |  |  | 51.6 |  |  | 2.3 |  |  | 8.9 |  |  | 37.2 |  |  | 187.9 |
Depreciation and amortization | 1.5 |  |  | 0.6 |  |  | — |  |  | 0.8 |  |  | 3.3 |  |  | 6.2 |
Operating expenses | 282.4 |  |  | 159.6 |  |  | 13.7 |  |  | 14.1 |  |  | 40.5 |  |  | 510.3 |
Operating income (loss) | $ | 57.8 |  |  | $ | 38.8 |  |  | $ | 1.2 |  |  | $ | (9.7) |  |  | $ | (40.5) |  |  | $ | 47.6 |
| For the Three-Month Period Ended June 30, 2021
| Home Health |  | Hospice |  | Personal Care |  | High Acuity Care |  | Other |  | Total
Net service revenue | $ | 349.3 |  |  | $ | 197.9 |  |  | $ | 17.0 |  |  | $ | — |  |  | $ | — |  |  | $ | 564.2 |
Other operating income | 2.3 |  |  | 2.3 |  |  | — |  |  | — |  |  | — |  |  | 4.6 |
Cost of service, excluding depreciation and amortization | 190.4 |  |  | 105.2 |  |  | 13.1 |  |  | — |  |  | — |  |  | 308.7 |
General and administrative expenses | 81.3 |  |  | 48.4 |  |  | 3.2 |  |  | — |  |  | 42.4 |  |  | 175.3 |
Depreciation and amortization | 1.2 |  |  | 0.7 |  |  | — |  |  | — |  |  | 4.8 |  |  | 6.7 |
Operating expenses | 272.9 |  |  | 154.3 |  |  | 16.3 |  |  | — |  |  | 47.2 |  |  | 490.7 |
Operating income (loss) | $ | 78.7 |  |  | $ | 45.9 |  |  | $ | 0.7 |  |  | $ | — |  |  | $ | (47.2) |  |  | $ | 78.1 |
| For the Six-Month Period Ended June 30, 2022
| Home Health |  | Hospice |  | Personal Care |  | High Acuity Care |  | Other |  | Total
Net service revenue | $ | 675.6 |  |  | $ | 391.4 |  |  | $ | 28.9 |  |  | $ | 7.2 |  |  | $ | — |  |  | $ | 1,103.1 |
Cost of service, excluding depreciation and amortization | 378.0 |  |  | 213.8 |  |  | 22.2 |  |  | 7.0 |  |  | — |  |  | 621.0 |
General and administrative expenses | 171.1 |  |  | 102.9 |  |  | 4.5 |  |  | 15.9 |  |  | 77.9 |  |  | 372.3 |
Depreciation and amortization | 2.4 |  |  | 1.3 |  |  | 0.1 |  |  | 1.6 |  |  | 8.8 |  |  | 14.2 |
Operating expenses | 551.5 |  |  | 318.0 |  |  | 26.8 |  |  | 24.5 |  |  | 86.7 |  |  | 1,007.5 |
Operating income (loss) | $ | 124.1 |  |  | $ | 73.4 |  |  | $ | 2.1 |  |  | $ | (17.3) |  |  | $ | (86.7) |  |  | $ | 95.6 |
| For the Six-Month Period Ended June 30, 2021
| Home Health |  | Hospice |  | Personal Care |  | High Acuity Care |  | Other |  | Total
Net service revenue | $ | 677.9 |  |  | $ | 389.4 |  |  | $ | 34.0 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,101.3 |
Other operating income | 7.3 |  |  | 6.0 |  |  | — |  |  | — |  |  | — |  |  | 13.3 |
Cost of service, excluding depreciation and amortization | 373.4 |  |  | 206.8 |  |  | 25.7 |  |  | — |  |  | — |  |  | 605.9 |
General and administrative expenses | 161.4 |  |  | 94.9 |  |  | 6.2 |  |  | — |  |  | 84.9 |  |  | 347.4 |
Depreciation and amortization | 2.2 |  |  | 1.3 |  |  | 0.1 |  |  | — |  |  | 10.7 |  |  | 14.3 |
Operating expenses | 537.0 |  |  | 303.0 |  |  | 32.0 |  |  | — |  |  | 95.6 |  |  | 967.6 |
Operating income (loss) | $ | 148.2 |  |  | $ | 92.4 |  |  | $ | 2.0 |  |  | $ | — |  |  | $ | (95.6) |  |  | $ | 147.0 |

25

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
8. SHARE REPURCHASES
On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we could repurchase up to $100 million of our outstanding common stock through December 31, 2021 (the "2021 Share Repurchase Program").
Under the terms of the 2021 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.
Pursuant to this program, we repurchased 4,757 shares of our common stock at a weighted average price of $249.72 per share and a total cost of approximately $1 million during the three-month period ended June 30, 2021 and 297,105 shares of our common stock at a weighted average price of $249.29 per share and a total cost of approximately $74 million during the six-month period ended June 30, 2021. The repurchased shares were classified as treasury shares. The 2021 Share Repurchase Program expired on December 31, 2021.
On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through December 31, 2022. This program commenced upon the completion of the Company's 2021 Share Repurchase Program (the "New Share Repurchase Program").
Under the terms of the New Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.
Pursuant to this program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17 million during the three and six-month periods ended June 30, 2022. The repurchased shares are classified as treasury shares.
9. RELATED PARTY TRANSACTIONS
We have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs totaling $2.3 million and $4.7 million during the three and six-month periods ended June 30, 2022, respectively, and $1.3 million and $2.6 million during the three and six-month periods ended June 30, 2021, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.
26

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three and six-month periods ended June 30, 2022. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein and the consolidated financial statements and notes and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on February 24, 2022 (the “Form 10-K”), which are incorporated herein by this reference. Historical results that appear in the condensed consolidated financial statements should not be interpreted as being indicative of future operations.
Unless otherwise provided, “Amedisys,” “we,” “our,” and “the Company” refer to Amedisys, Inc. and our consolidated subsidiaries.
Overview
We are a provider of high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population, with approximately 74% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2022 and approximately 75% of our consolidated net service revenue derived from Medicare for the three and six-month periods ended June 30, 2021.
Our operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa Health ("Contessa") on August 1, 2021, delivers the essential elements of inpatient hospital and skilled nursing facility ("SNF") care to patients in their homes. As of June 30, 2022, we owned and operated 353 Medicare-certified home health care centers, 174 Medicare-certified hospice care centers, 14 personal-care care centers and 9 admitting high acuity care joint ventures in 38 states within the United States and the District of Columbia.
Care Centers Summary (Includes Unconsolidated Joint Ventures)

| Home Health |  | Hospice |  | Personal Care |  | High Acuity Care
As of December 31, 2021 | 331 |  |  | 175 |  |  | 14 |  |  | 8 |
Acquisitions/Startups/Denovos | 24 |  |  | — |  |  | — |  |  | 1 |
Closed/Consolidated | (2) |  |  | (1) |  |  | — |  |  | — |
As of June 30, 2022 | 353 |  |  | 174 |  |  | 14 |  |  | 9 |

Recent Developments
Acquisitions
On April 1, 2022, we acquired fifteen home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City and Care Connection of Cincinnati ("Evolution"), for a purchase price of $68 million.
Additionally, on April 1, 2022, we acquired two home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $25 million.
Governmental Inquiries and Investigations and Other Litigation
See Note 6 – Commitments and Contingencies to our condensed consolidated financial statements for a discussion of and updates regarding legal proceedings and investigations we are involved in. No assurances can be given as to the timing or outcome of these items.
27

The Centers for Medicare and Medicaid Services ("CMS") Payment Updates
Hospice
On July 29, 2021, CMS issued the final rule to update hospice payment rates and the wage index for fiscal year 2022, effective for services provided beginning October 1, 2021. CMS estimated hospices serving Medicare beneficiaries would see a 2.0% increase in payments. This increase was the result of a 2.7% market basket adjustment as required under the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act (collectively, "PPACA") less a 0.7% productivity adjustment. Additionally, CMS increased the aggregate cap amount by 2.0% to $31,298. The final rule also rebased the labor shares for all four levels of care, included updates to the hospice conditions of participation ("COPs"), which made permanent certain flexibilities allowed during the novel coronavirus pandemic ("COVID-19") public health emergency, and finalized changes to the Hospice Quality Reporting Program. Based on our analysis of the final rule, we estimated that our impact would be in line with the 2.0% increase.
On July 27, 2022, CMS issued the final rule to update hospice payment rates and the wage index for fiscal year 2023, effective for services provided beginning October 1, 2022. CMS estimates hospices serving Medicare beneficiaries will see a 3.8% increase in payments. This increase is the result of a 4.1% market basket adjustment as required under PPACA less a 0.3% productivity adjustment. Additionally, CMS proposed to increase the aggregate cap amount by 3.8% to $32,487. Based on our analysis of the proposed rule, we expect our impact to be in line with the 3.8% increase.
Home Health
On November 2, 2021, CMS issued the Home Health Final Rule for Medicare home health providers for calendar year 2022. CMS estimated that the final rule would result in a 3.2% increase in payments to home health providers. This increase was the result of a 2.6% payment update (3.1% market basket adjustment less a 0.5% productivity adjustment) plus a 0.7% fixed-dollar loss ratio adjustment, reduced by 0.1% for the rural add-on. Based on our analysis of the final rule, we estimated that our impact would be in line with the 3.2% increase.
The final rule also provided for the expansion of the Home Health Value-Based Purchasing ("HHVBP") model to all 50 states beginning January 1, 2023 with calendar year 2023 being the first performance year and calendar year 2025 being the first payment year with a proposed maximum payment adjustment, up or down, of 5%.
On June 17, 2022, CMS issued a proposed payment change for Medicare home health providers for calendar year 2023. CMS estimates that the proposed rule will result in a 4.2% decrease in payments to home health providers. This decrease is the result of a 2.9% payment update (3.3% market basket adjustment less a 0.4% productivity adjustment) less a permanent adjustment of 6.9% (derived from a 7.69% behavioral assumption adjustment), reduced by 0.2% for the update to the fixed-dollar loss ratio ("FDL") used in determining outlier payments. This rule also proposes a permanent 5% cap on negative wage index changes for home health agencies. Based on our preliminary analysis of the proposed rule, we expect our impact to be in line with the 4.2% rate cut.
In addition to the 6.9% permanent adjustment, CMS is also considering a temporary adjustment of approximately $2 billion to offset overpayments in calendar years 2020 and 2021. CMS is not proposing to apply the temporary adjustment to calendar year 2023; however, CMS is soliciting comments on how to best apply the adjustment in the future.
A group of bipartisan lawmakers has introduced a bill, The Preserving Access to Home Health Act of 2022, which upon enactment, would pause the implementation of any temporary or permanent adjustments to the Medicare home health base payment rate until 2026. This would delay the cuts currently proposed by CMS and would allow time for the industry and CMS to work on a more reasonable methodology that adequately measures the impact of the transition to PDGM and fully accounts for the impacts that COVID-19 has had on utilization, patient mix and the level of care provided by home health agencies.
Sequestration
In March 2020, Congress passed the bipartisan Coronavirus Aid, Relief and Economic Security Act ("CARES Act") which provided for the suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. In December 2021, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act. This legislation extended the 2% suspension of sequestration through March 31, 2022; sequestration was reinstated as a 1% reduction to Medicare claim reimbursements for the period April 1, 2022 through June 30, 2022 and has been fully reinstated as a 2% reduction to Medicare claim reimbursements effective July 1, 2022. The reinstatement of sequestration will result in a reduction of our net service revenue for the remainder of the year.
Novel Coronavirus Pandemic ("COVID-19")
Our operations and financial performance continue to be impacted by COVID-19. The financial impacts of COVID-19 are discussed in further detail under "Results of Operations" below. While we currently believe that we have a reasonable view of
28

operations, the uncertainty created by COVID-19 could alter our outlook of the pandemic's impact on our consolidated financial condition, results of operations or cash flows. The following factors could potentially impact our performance: the increase or decrease in the number of COVID-19 cases nationwide; the severity and impacts of new variants of the virus; uncertainty regarding vaccine utilization rates and efficacy; staffing shortages due to clinician quarantines, the competitive labor market and federal, state and local vaccine mandates; the return of patient confidence to enter a hospital or a doctor's office; the utilization of elective procedures; the ability to have access to our patients in their homes and in facilities; supply chain disruption and our ability to find suitable alternative products at reasonable prices; cost normalization around personal protective equipment ("PPE"); and any future or prolonged shelter-in-place orders and other federal, state and local requirements. Potential impacts of COVID-19 on our results include lower revenue; higher salary and wage expense related to quarantine pay, contract clinicians, wage inflation, increased costs to hire and retain employees and training; and increased supply costs related to supply chain constraints, PPE and COVID-19 testing. The impacts to net service revenue may consist of the following:
•lower volumes due to interruption of the operations of our referral sources, patients' unwillingness to accept services and restrictions on access to facilities for hospice services;
•lower reimbursement due to missed visits resulting in an increase in low utilization payment adjustments ("LUPAs") and lost billing periods; and
•lower hospice average daily census due to a decline in our average length of stay.
On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for the following:
•$175 billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30 billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100 million from the first $30 billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2 million related to our joint venture care centers (equity method investments). We also acquired approximately $6 million of PRF funds in connection with the acquisition of AseraCare Hospice. Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021.
For our wholly-owned subsidiaries, we only utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred is reflected in other operating income within our condensed consolidated statements of operations.
•The temporary suspension of sequestration for the period May 1, 2020 through December 31, 2020. See The Centers for Medicare and Medicaid Services ("CMS") Payment Updates above for details on extensions beyond December 31, 2020.
•The deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. During 2020, we deferred approximately $55 million of social security tax. Approximately $27 million was paid during December 2021; the remaining balance is due on December 31, 2022 and is reflected in payroll and employee benefits within our condensed consolidated balance sheet.
•The temporary suspension of Medicare patient coverage criteria and documentation and care requirements and the expansion of providing home health and hospice care to patients via telehealth.
•The ability for non-physician practitioners to certify for home health, order home health services, establish and review plans of care and certify and recertify eligibility.
The well-being of our employees has been one of our top priorities during the pandemic. We have taken the following steps to support our employees: implemented paid leave during any required quarantine periods; awarded bonuses to our clinicians and caregivers who saw patients during the pandemic; completed an early cash pay-out of employee paid-time-off; instituted work-from-home arrangements for our corporate and administrative support employees; allowed employees to temporarily suspend any 401(k) plan loan deductions and offered employees the option of making a withdrawal from their 401(k) plan for coronavirus-related distributions without incurring the additional 10% early withdrawal penalty; expanded access to telehealth services to all employees; provided access to COVID-19 self-test kits to all employees and created a COVID-19 Resource Center, available 24 hours a day, seven days a week for employees to access educational materials, safety documents, policies, clinical protocols and operational metrics.
29

The safety of our clinicians and patients has also been a focus, and as a result, we have made the following business changes: developed clinical protocols for COVID-19 testing, proper usage of PPE, caring for COVID-positive patients and maintaining safety measures in our care centers; researched each state's vaccination plan to develop a state by state protocol to work with local health departments and other health systems to obtain vaccine appointments for our clinical staff; implemented software enabling us to track staff that have been vaccinated; procured PPE; and created a centralized distribution center for all critical PPE, allowing us to flex our supplies on a care center by care center basis, based on need and demand.
Results of Operations
Three-Month Period Ended June 30, 2022 Compared to the Three-Month Period Ended June 30, 2021
Consolidated
The following table summarizes our consolidated results of operations (amounts in millions):

| For the Three-Month Periods Ended June 30,
| 2022 |  | 2021
Net service revenue | $ | 557.9 |  |  | $ | 564.2 |
Other operating income | — |  |  | 4.6 |
Cost of service, excluding depreciation and amortization | 316.2 |  |  | 308.7 |
Gross margin, excluding depreciation and amortization | 241.7 |  |  | 260.1 |
% of revenue | 43.3 | % |  | 46.1 | %
Other operating expenses | 187.9 |  |  | 175.3 |
% of revenue | 33.7 | % |  | 31.1 | %
Depreciation and amortization | 6.2 |  |  | 6.7 |
Operating income | 47.6 |  |  | 78.1 |
Total other (expense) income | (7.3) |  |  | 31.0 |
Income tax expense | (11.3) |  |  | (28.5) |
Effective income tax rate | 28.0 | % |  | 26.1 | %
Net income | 29.0 |  |  | 80.6 |
Net loss (income) attributable to noncontrolling interests | 0.6 |  |  | (0.5) |
Net income attributable to Amedisys, Inc. | $ | 29.6 |  |  | $ | 80.1 |

On a consolidated basis, our operating income decreased $31 million on a $6 million decrease in net service revenue. The year-over-year decrease in operating income is primarily due to the acquisitions of Contessa on August 1, 2021 and Evolution and AssistedCare on April 1, 2022 (which combined contributed $18 million in revenue and an operating loss of $11 million), an $8 million accrual related to our Infinity Home Care, L.L.C. Zone Program Integrity Contractor ("Infinity ZPIC") audits and a $7 million favorable adjustment recorded in the prior year related to our U.S. Department of Justice ("DOJ") matters (see Note 6 – Commitments and Contingencies to our condensed consolidated financial statements for additional information regarding both the Infinity ZPIC and DOJ matters).
Excluding our acquisitions and the Infinity ZPIC and DOJ matters, our operating income decreased $5 million on a $9 million decrease in net service revenue primarily due to a year over year decline in our home health volumes, the reinstatement of sequestration at 1%, a shift in our home health patient mix from episodic payors to lower margin per visit payors, a decrease in our other operating income due to the expiration of the CARES Act PRF funds and an increase in our cost of service resulting from labor cost increases. We were able to partially overcome these items through improvements in home health clinician utilization and reductions in our hospice staffing levels. Additionally, our year over year results were positively impacted by rate increases.
As noted above, we received CARES Act PRF funds in 2020 which were used to cover COVID-19 expenses incurred by our home health and hospice segments through June 30, 2021. We recorded income related to these funds totaling $5 million in other operating income within our condensed consolidated statements of operations during the three-month period ended June 30, 2021. This income fully offset the COVID-19 costs incurred during this period, which totaled $5 million. Due to the expiration of the CARES Act PRF funds on June 30, 2021, we were not able to recognize any operating income during the three-month period ended June 30, 2022 to offset the $2 million of COVID-19 costs incurred during this period.
30

Our operating results reflect a $13 million increase in our other operating expenses compared to prior year. Excluding our acquisitions, our other operating expenses were flat as the addition of resources to support growth, planned wage increases, higher travel and training spend, higher acquisition and integration costs, severance and lease termination costs related to hospice care center closures and consolidations and increased information technology fees were partially offset by higher gains on the sale of fleet vehicles and a favorable legal settlement.
Total other (expense) income includes the following items (amounts in millions):

| For the Three-Month Periods Ended June 30,
| 2022 |  | 2021
Interest expense, net | $ | (8.3) |  |  | $ | (1.9) |
Equity in earnings from equity method investments | 0.7 |  |  | 1.3 |
Gain on equity method investment | — |  |  | 31.1 |
Miscellaneous, net | 0.3 |  |  | 0.5 |
Total other (expense) income | $ | (7.3) |  |  | $ | 31.0 |

Interest expense, net increased $6 million year over year as a result of interest accrued in conjunction with the Infinity ZPIC audits discussed above and outstanding term loan borrowings under our Second Amended Credit Agreement (see Note 5 – Long-Term Obligations to our condensed consolidated financial statements for additional information regarding our Second Amended Credit Agreement). Gain on equity method investments for the prior year includes a $31 million gain related to our investment in Medalogix (see Note 1 – Nature of Operations, Consolidation and Presentation of Financial Statements to our condensed consolidated financial statements for additional information).
31

Home Health Segment
The following table summarizes our home health segment results of operations:

| For the Three-Month Periods Ended June 30,
| 2022 |  | 2021
Financial Information (in millions): |  |  |
Medicare | $ | 222.0 |  |  | $ | 234.8 |
Non-Medicare | 118.2 |  |  | 114.5 |
Net service revenue | 340.2 |  |  | 349.3 |
Other operating income | — |  |  | 2.3 |
Cost of service | 193.0 |  |  | 190.4 |
Gross margin | 147.2 |  |  | 161.2 |
Other operating expenses | 87.9 |  |  | 81.3 |
Depreciation and amortization | 1.5 |  |  | 1.2 |
Operating income | $ | 57.8 |  |  | $ | 78.7 |
Same Store Growth (1): |  |  |
Medicare revenue | (9 | %) |  | 22 | %
Non-Medicare revenue | (3 | %) |  | 18 | %
Total admissions | — | % |  | 20 | %
Total volume (2) | (2 | %) |  | 12 | %
Key Statistical Data - Total (3): |  |  |
Admissions | 93,560 |  |  | 89,371 |
Recertifications | 45,720 |  |  | 46,014 |
Total volume | 139,280 |  |  | 135,385 |
Medicare completed episodes | 77,880 |  |  | 79,188 |
Average Medicare revenue per completed episode (4) | $ | 3,048 |  |  | $ | 2,986 |
Medicare visits per completed episode (5) | 13.2 |  |  | 14.2 |
Visiting clinician cost per visit | $ | 97.41 |  |  | $ | 91.24 |
Clinical manager cost per visit | 10.67 |  |  | 9.31 |
Total cost per visit | $ | 108.08 |  |  | $ | 100.55 |
Visits | 1,785,763 |  |  | 1,894,006 |

(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total volume includes all admissions and recertifications.
(3) Total includes acquisitions, start-ups and denovos.
(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration for the period January 1, 2021 through March 31, 2022 and the reinstatement of sequestration at 1% for the period April 1, 2022 through June 30, 2022.
(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
32

Operating Results
Overall, our operating income decreased $21 million on a $9 million decrease in net service revenue. Our year over year results were impacted by the April 1, 2022 acquisitions of Evolution and AssistedCare, which contributed revenue of $14 million and an operating loss of $1 million to the quarter, as well as an $8 million accrual related to our Infinity ZPIC audits discussed above. Excluding our acquisitions and the Infinity ZPIC, our operating income decreased $12 million on a $15 million decrease in net service revenue primarily due to a year over year decline in volumes, the reinstatement of sequestration at 1%, a shift in our patient mix from episodic payors to lower margin per visit payors, the expiration of the CARES Act PRF funds and increases in our labor costs, integration costs and other operating expenses. These items were partially offset by the increase in reimbursement as well as improvement in our operating performance driven by improvements in clinician utilization.
Net Service Revenue
Our net service revenue decreased $9 million. Excluding our April 1, 2022 acquisitions of Evolution and AssistedCare and the Infinity ZPIC audits discussed above, our net service revenue decreased $15 million primarily due to a year over year decline in volumes and the reinstatement of sequestration at 1%. These items were partially offset by the 3.2% increase in reimbursement effective January 1, 2022.
Other Operating Income
Other operating income consists of the recognition of funds received from the CARES Act PRF, which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $2 million during the three-month period ended June 30, 2021. We incurred COVID-19 related costs totaling $2 million during the three-month period ended June 30, 2022; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, premiums paid to contract clinicians, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations.
Cost of Service, Excluding Depreciation and Amortization
Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor the overall delivery of care. Overall, our total cost of service increased 1% primarily due to a 7% increase in our total cost per visit partially offset by a 6% decrease in total visits, resulting from improvements in clinician utilization, as evidenced by a decline of 1.0 visits per completed episode year over year. The 7% increase in our total cost per visit is primarily due to planned wage increases, higher new hire pay, an increase in salaried employees (partially due to our recent acquisitions), wage inflation, increased costs to hire and retain employees, visit mix and higher fuel prices partially offset by a decrease in COVID-19 costs. In addition, while we compensate our clinicians on a per visit basis, there is a fixed cost component of our cost structure which also resulted in an increase in our cost per visit due to the significant decline in visits year over year.
Other Operating Expenses
Other operating expenses increased $7 million. Excluding our acquisitions, other operating expenses increased $3 million primarily due to planned wage increases, the addition of resources to support volume growth, higher travel and training spend and higher information technology fees.
33

Hospice Segment
The following table summarizes our hospice segment results of operations:

| For the Three-Month Periods Ended June 30,
| 2022 |  | 2021
Financial Information (in millions): |  |  |
Medicare | $ | 187.5 |  |  | $ | 186.9 |
Non-Medicare | 10.9 |  |  | 11.0 |
Net service revenue | 198.4 |  |  | 197.9 |
Other operating income | — |  |  | 2.3 |
Cost of service | 107.4 |  |  | 105.2 |
Gross margin | 91.0 |  |  | 95.0 |
Other operating expenses | 51.6 |  |  | 48.4 |
Depreciation and amortization | 0.6 |  |  | 0.7 |
Operating income | $ | 38.8 |  |  | $ | 45.9 |
Same Store Growth (1): |  |  |
Medicare revenue | — | % |  | 2 | %
Hospice admissions | 6 | % |  | 2 | %
Average daily census | — | % |  | (3 | %)
Key Statistical Data - Total (2): |  |  |
Hospice admissions | 13,359 |  |  | 12,675 |
Average daily census | 13,249 |  |  | 13,254 |
Revenue per day, net | $ | 164.55 |  |  | $ | 164.10 |
Cost of service per day | $ | 89.05 |  |  | $ | 87.17 |
Average discharge length of stay | 87 |  |  | 97 |

(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total includes acquisitions and denovos.
Operating Results
Overall, our operating income decreased $7 million on a $1 million increase in net service revenue. Excluding a $7 million favorable adjustment recorded in the prior year related to our DOJ matters (see Note 6 - Commitments and Contingencies to our condensed consolidated financial statements for additional information), operating income was flat on an $8 million increase in net service revenue. The quarter was impacted by the reinstatement of sequestration at 1%, an increase in our labor costs, a decrease in other operating income due to the expiration of the CARES Act PRF funds and an increase in our other operating expenses which were partially offset by the increase in reimbursement effective October 1, 2021, lower revenue adjustments and a reduction in staffing levels.
Net Service Revenue
Excluding the DOJ matters in prior year mentioned above, our net service revenue increased $8 million primarily due to the increase in reimbursement effective October 1, 2021 and lower revenue adjustments partially offset by the reinstatement of sequestration at 1%. Despite an increase in admissions, our same store average daily census, which is the main driver of hospice revenue, was flat year over year primarily due to a decline in our length of stay over the past year resulting from a delay in the timing of patients coming onto service and an increase in the discharge rate of our patients. We have recently seen an increase in our length of stay, which has helped to drive a 2.5% sequential increase in our second quarter average daily census compared to the first quarter.
34

Other Operating Income
Other operating income consists of the recognition of funds received from the CARES Act PRF, which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $2 million during the three-month period ended June 30, 2021. We incurred COVID-19 related costs totaling less than $1 million during the three-month period ended June 30, 2022; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations.
Cost of Service, Excluding Depreciation and Amortization
Our hospice cost of service increased 2% primarily due to a 2% increase in our cost of service per day. The increase in our cost of service per day is due to planned wage increases, wage inflation, increased costs to hire and retain employees and higher fuel prices partially offset by lower COVID-19 costs.
Other Operating Expenses
Other operating expenses increased $3 million primarily due to planned wage increases, higher travel and training spend, higher information technology fees and severance and lease termination costs associated with care center closures and consolidations.
Personal Care Segment
The following table summarizes our personal care segment results of operations:

| For the Three-Month Periods Ended June 30,
| 2022 |  | 2021
Financial Information (in millions): |  |  |
Medicare | $ | — |  |  | $ | — |
Non-Medicare | 14.9 |  |  | 17.0 |
Net service revenue | 14.9 |  |  | 17.0 |
Other operating income | — |  |  | — |
Cost of service | 11.4 |  |  | 13.1 |
Gross margin | 3.5 |  |  | 3.9 |
Other operating expenses | 2.3 |  |  | 3.2 |
Depreciation and amortization | — |  |  | — |
Operating income | $ | 1.2 |  |  | $ | 0.7 |
Key Statistical Data - Total: |  |  |
Billable hours | 472,523 |  |  | 609,301 |
Clients served | 7,759 |  |  | 9,371 |
Shifts | 201,996 |  |  | 260,897 |
Revenue per hour | $ | 31.59 |  |  | $ | 27.95 |
Revenue per shift | $ | 73.89 |  |  | $ | 65.29 |
Hours per shift | 2.3 |  | 2.3

Operating Results
Operating income related to our personal care segment increased $1 million on a $2 million decrease in net service revenue. The decrease in net service revenue is due to the impact of COVID-19 and staffing shortages partially offset by rate increases. These impacts have been mitigated by a reduction in our cost of service as most of our personal care employees are paid on an hourly basis as well as a reduction in our other operating expenses.
35

High Acuity Care Segment
The following table summarizes our high acuity care segment results of operations:

| For the Three-Month Periods Ended June 30,
| 2022 |  | 2021
Financial Information (in millions): |  |  |
Medicare | $ | 1.7 |  |  | $ | — |
Non-Medicare | 2.7 |  |  | — |
Net service revenue | 4.4 |  |  | — |
Other operating income | — |  |  | — |
Cost of service | 4.4 |  |  | — |
Gross margin | — |  |  | — |
Other operating expenses | 8.9 |  |  | — |
Depreciation and amortization | 0.8 |  |  | — |
Operating loss | $ | (9.7) |  |  | $ | — |
Key Statistical Data - Total: |  |  |
Full risk admissions | 104 |  |  | — |
Limited risk admissions | 241 |  |  | — |
Total admissions | 345 |  |  | — |
Full risk revenue per episode | $ | 11,278 |  |  | $ | — |
Limited risk revenue per episode | $ | 5,316 |  |  | $ | — |
Number of admitting joint ventures | 9 |  |  | — |

Operating Results
Overall, our high acuity care segment generated revenue totaling $4 million and an operating loss of $10 million. Although we expect our high acuity care segment to continue to generate operating losses throughout the remainder of the year, we also expect improvement in our operating income as we leverage our operating structure through growth in current and future joint ventures and expansion into new lines of business such as palliative care at home.
Net Service Revenue
Our high acuity care segment provides home recovery care services for high acuity patients on either a full risk or limited risk basis, each with different reimbursement arrangements. Full risk admissions are admissions for which we assume the financial risk for all related healthcare services during a 30-day or 60-day episodic period in exchange for a fixed contracted bundled rate. Limited risk admissions are admissions for which we assume the risk for certain healthcare services during a shorter acute phase period (equivalent to an inpatient hospital stay) in exchange for a contracted per diem payment.
Additionally, on March 23, 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing joint ventures. As a result, our high acuity care segment includes revenue totaling approximately $2 million related to this joint venture's home health operations.
Cost of Service, Excluding Depreciation and Amortization
Our cost of service consists primarily of medical costs associated with direct clinician care provided to our patients during the applicable episode period, whether such care was provided on the day of program admission, in the patients’ homes or via telehealth, as well as costs associated with our virtual care unit (“VCU”), which enables us to provide monitoring services and facilitates virtual patient rounding visits via telehealth. We continue to invest in the infrastructure of our VCU in anticipation of future growth.
36

Other Operating Expenses
Other operating expenses primarily consist of salaries and benefits. We have made significant investments to build the clinical, operational and technological infrastructure necessary to support the development and future growth of home recovery care programs on a national scale. We have employees at both the local market level and at our corporate offices.
Corporate
The following table summarizes our corporate results of operations:

| For the Three-Month Periods Ended June 30,
| 2022 |  | 2021
Financial Information (in millions): |  |  |
Other operating expenses | $ | 37.2 |  |  | $ | 42.4 |
Depreciation and amortization | 3.3 |  |  | 4.8 |
Total operating expenses | $ | 40.5 |  |  | $ | 47.2 |

Corporate expenses consist of costs related to our executive management and corporate and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.
Corporate other operating expenses decreased approximately $5 million during the three-month period ended June 30, 2022 primarily due to higher gains on the sale of fleet vehicles, a favorable legal settlement and lower spend in various cost categories partially offset by higher acquisition and integration costs.
Six-Month Period Ended June 30, 2022 Compared to the Six-Month Period Ended June 30, 2021
Consolidated
The following table summarizes our consolidated results of operations (amounts in millions):

| For the Six-Month Periods Ended June 30,
| 2022 |  | 2021
Net service revenue | $ | 1,103.1 |  |  | $ | 1,101.3 |
Other operating income | — |  |  | 13.3 |
Cost of service, excluding depreciation and amortization | 621.0 |  |  | 605.9 |
Gross margin, excluding depreciation and amortization | 482.1 |  |  | 508.7 |
% of revenue | 43.7 | % |  | 46.2 | %
Other operating expenses | 372.3 |  |  | 347.4 |
% of revenue | 33.8 | % |  | 31.5 | %
Depreciation and amortization | 14.2 |  |  | 14.3 |
Operating income | 95.6 |  |  | 147.0 |
Total other (expense) income | (11.5) |  |  | 30.4 |
Income tax expense | (23.3) |  |  | (46.5) |
Effective income tax rate | 27.8 | % |  | 26.2 | %
Net income | 60.8 |  |  | 130.9 |
Net loss (income) attributable to noncontrolling interests | 0.5 |  |  | (0.9) |
Net income attributable to Amedisys, Inc. | $ | 61.3 |  |  | $ | 130.0 |

37

On a consolidated basis, our operating income decreased $51 million on a $2 million increase in net service revenue. The year-over-year decrease in operating income is primarily due to the acquisitions of Contessa on August 1, 2021 and Evolution and AssistedCare on April 1, 2022 (which combined contributed $21 million in revenue and an operating loss of $19 million), an $8 million accrual related to our Infinity ZPIC audits and a $7 million favorable adjustment recorded in the prior year related to our DOJ matters (see Note 6 – Commitments and Contingencies to our condensed consolidated financial statements for additional information regarding both the ZPIC and DOJ matters).
Excluding our acquisitions, the Infinity ZPIC and the DOJ matters, our operating income decreased $17 million on a $4 million decrease in net service revenue primarily due to a decline in our home health volumes, a decline in our hospice average daily census, which is the main driver of hospice revenue, the reinstatement of sequestration at 1% effective April 1, 2022, a decrease in our other operating income due to the expiration of the CARES Act PRF funds, an increase in our cost of service resulting from labor cost increases and in increase in our other operating expenses. Partially offsetting these items, our results were positively impacted by rate increases, improvements in clinician utilization and reductions in hospice staffing levels.
As noted above, we received CARES Act PRF funds in 2020 which were used to cover COVID-19 expenses incurred by our home health and hospice segments through June 30, 2021. We recorded income related to these funds totaling $13 million in other operating income within our condensed consolidated statements of operations during the six-month period ended June 30, 2021. This income fully offset the COVID-19 costs incurred during this period, which totaled $13 million. Due to the expiration of the CARES Act PRF funds on June 30, 2021, we were not able to recognize any operating income during the six-month period ended June 30, 2022 to offset the $6 million of COVID-19 costs incurred during this period.
Our operating results reflect a $25 million increase in our other operating expenses compared to prior year. Excluding our acquisitions, our other operating expenses increased $5 million (1%) due to the addition of resources to support growth, planned wage increases, higher travel and training spend, higher acquisition and integration costs, severance and lease termination costs related to hospice closures and consolidations and increased information technology fees partially offset by higher gains on the sale of fleet vehicles and a favorable legal settlement.
Total other (expense) income includes the following items (amounts in millions):

| For the Six-Month Periods Ended June 30,
| 2022 |  | 2021
Interest expense, net | $ | (11.5) |  |  | $ | (4.0) |
Equity in (loss) earnings from equity method investments | (0.7) |  |  | 2.5 |
Gain on equity method investments | — |  |  | 31.1 |
Miscellaneous, net | 0.7 |  |  | 0.8 |
Total other (expense) income | $ | (11.5) |  |  | $ | 30.4 |

Interest expense, net increased $8 million year over year as a result of interest accrued in conjunction with the Infinity ZPIC audits discussed above and outstanding term loan borrowings under our Second Amended Credit Agreement (see Note 5 – Long-Term Obligations to our condensed consolidated financial statements for additional information regarding our Second Amended Credit Agreement). Gain on equity method investments for the prior year includes a $31 million gain related to our investment in Medalogix (see Note 1 – Nature of Operations, Consolidation and Presentation of Financial Statements to our condensed consolidated financial statements for additional information).
38

Home Health Segment
The following table summarizes our home health segment results of operations:

| For the Six-Month Periods Ended June 30,
| 2022 |  | 2021
Financial Information (in millions): |  |  |
Medicare | $ | 446.1 |  |  | $ | 456.2 |
Non-Medicare | 229.5 |  |  | 221.7 |
Net service revenue | 675.6 |  |  | 677.9 |
Other operating income | — |  |  | 7.3 |
Cost of service | 378.0 |  |  | 373.4 |
Gross margin | 297.6 |  |  | 311.8 |
Other operating expenses | 171.1 |  |  | 161.4 |
Depreciation and amortization | 2.4 |  |  | 2.2 |
Operating income | $ | 124.1 |  |  | $ | 148.2 |
Same Store Growth (1): |  |  |
Medicare revenue | (4 | %) |  | 15 | %
Non-Medicare revenue | — | % |  | 13 | %
Total admissions | 1 | % |  | 12 | %
Total volume (2) | (1 | %) |  | 9 | %
Key Statistical Data - Total (3): |  |  |
Admissions | 185,274 |  |  | 179,201 |
Recertifications | 88,570 |  |  | 89,825 |
Total volume | 273,844 |  |  | 269,026 |
Medicare completed episodes | 152,286 |  |  | 154,520 |
Average Medicare revenue per completed episode (4) | $ | 3,031 |  |  | $ | 2,959 |
Medicare visits per completed episode (5) | 13.1 |  |  | 14.1 |
Visiting clinician cost per visit | $ | 97.31 |  |  | $ | 90.79 |
Clinical manager cost per visit | 10.67 |  |  | 9.40 |
Total cost per visit | $ | 107.98 |  |  | $ | 100.19 |
Visits | 3,500,907 |  |  | 3,726,918 |

(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total volume includes all admissions and recertifications.
(3) Total includes acquisitions, start-ups and denovos.
(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration for the period January 1, 2021 through March 31, 2022 and the reinstatement of sequestration at 1% for the period April 1, 2022 through June 30, 2022.
(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
39

Operating Results
Overall, our operating income decreased $24 million on a $2 million decrease in net service revenue. Our year over year results were impacted by the April 1, 2022 acquisitions of Evolution and AssistedCare, which contributed revenue of $14 million and an operating loss of $1 million to the six-month period ended June 30, 2022, as well as an $8 million accrual related to our Infinity ZPIC audits discussed above. Excluding our acquisitions and the Infinity ZPIC, our operating income decreased $15 million on an $8 million decrease in net service revenue primarily due to a year over year decline in volumes and the impact of the COVID-19 Omicron variant in the first quarter which drove the highest number of clinician quarantines since the start of the pandemic, the reinstatement of sequestration at 1% effective April 1, 2022, the expiration of the CARES Act PRF funds, an increase in our labor costs and an increase in our other operating expenses. These items were partially offset by the increase in reimbursement as well as improvement in our operating performance driven by improvements in clinician utilization.
Net Service Revenue
Our net service revenue decreased $2 million (less than 1%). Excluding our April 1, 2022 acquisitions of Evolution and AssistedCare and the Infinity ZPIC audits described above, our net service revenue decreased $8 million primarily due to a year over year decline in volumes and the impact of the Omicron variant in the first quarter, which drove the highest number of clinician quarantines since the start of the pandemic, as well as the reinstatement of sequestration at 1% effective April 1, 2022. These items were partially offset by the 3.2% increase in reimbursement effective January 1, 2022.
Other Operating Income
Other operating income consists of the recognition of funds received from the CARES Act PRF, which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $7 million during the six-month period ended June 30, 2021. We incurred COVID-19 related costs totaling $4 million during the six-month period ended June 30, 2022; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, premiums paid to contract clinicians, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations.
Cost of Service, Excluding Depreciation and Amortization
Overall, our total cost of service increased 1% primarily due to an 8% increase in our total cost per visit partially offset by a 6% decrease in total visits, resulting from improvements in clinician utilization, as evidenced by a decline of 1.0 visits per completed episode year over year. The 8% increase in our total cost per visit is primarily due to planned wage increases, higher new hire pay, an increase in salaried employees (partially due to our recent acquisitions), wage inflation, increased costs to hire and retain employees, visit mix and higher fuel prices partially offset by a decrease in COVID-19 costs. In addition, while we compensate our clinicians on a per visit basis, there is a fixed cost component of our cost structure which also resulted in an increase in our cost per visit due to the significant decline in visits year over year.
Other Operating Expenses
Other operating expenses increased $10 million. Excluding our acquisitions, other operating expenses increased $6 million primarily due to planned wage increases, the addition of resources to support volume growth, higher travel and training spend and higher information technology fees.
40

Hospice Segment
The following table summarizes our hospice segment results of operations:

| For the Six-Month Periods Ended June 30,
| 2022 |  | 2021
Financial Information (in millions): |  |  |
Medicare | $ | 370.0 |  |  | $ | 368.4 |
Non-Medicare | 21.4 |  |  | 21.0 |
Net service revenue | 391.4 |  |  | 389.4 |
Other operating income | — |  |  | 6.0 |
Cost of service | 213.8 |  |  | 206.8 |
Gross margin | 177.6 |  |  | 188.6 |
Other operating expenses | 102.9 |  |  | 94.9 |
Depreciation and amortization | 1.3 |  |  | 1.3 |
Operating income | $ | 73.4 |  |  | $ | 92.4 |
Same Store Growth (1): |  |  |
Medicare revenue | — | % |  | — | %
Hospice admissions | 4 | % |  | 3 | %
Average daily census | (1 | %) |  | (3 | %)
Key Statistical Data - Total (2): |  |  |
Hospice admissions | 27,245 |  |  | 26,358 |
Average daily census | 13,086 |  |  | 13,287 |
Revenue per day, net | $ | 165.28 |  |  | $ | 161.93 |
Cost of service per day | $ | 90.24 |  |  | $ | 85.99 |
Average discharge length of stay | 88 |  |  | 95 |

(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total includes acquisitions and denovos.
Operating Results
Overall, our operating income decreased $19 million on a $2 million increase in net service revenue. Excluding a $7 million favorable adjustment recorded in the prior year related to our DOJ matters (see Note 6 – Commitments and Contingencies to our condensed consolidated financial statements for additional information), operating income decreased $12 million on a $9 million increase in net service revenue primarily due to a decline in our average daily census, the reinstatement of sequestration at 1% effective April 1, 2022, an increase in our labor costs, a decrease in other operating income due to the expiration of the CARES Act PRF funds and an increase in our other operating expenses. These items were partially offset by the increase in reimbursement effective October 1, 2021, lower revenue adjustments and reductions in staffing levels.
Net Service Revenue
Excluding the DOJ matters in the prior year mentioned above, our net service revenue increased $9 million primarily due to the increase in reimbursement effective October 1, 2021 as well as lower revenue adjustments partially offset by a decline in our average daily census, which is the main driver of hospice revenue and the reinstatement of sequestration at 1% effective April 1, 2022. Our same store average daily census was down 1% year over year primarily due to a decline in our length of stay resulting from a delay in the timing of patients coming onto service and an increase in the discharge rate of our patients.
41

Other Operating Income
Other operating income consists of the recognition of funds received from the CARES Act PRF, which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $6 million during the six-month period ended June 30, 2021. We incurred COVID-19 related costs totaling $2 million during the six-month period ended June 30, 2022; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations.
Cost of Service, Excluding Depreciation and Amortization
Our hospice cost of service increased 3% primarily due to a 5% increase in our cost of service per day partially offset by a 1% decline in our average daily census. The increase in our cost of service per day is due to planned wage increases, wage inflation, higher costs associated with the utilization of contractors to supplement our staffing levels, increased costs to hire and retain employees and higher fuel prices partially offset by lower COVID-19 costs.
Other Operating Expenses
Other operating expenses increased $8 million primarily due to planned wage increases, the addition of resources to support volume growth, higher travel and training spend, higher information technology fees and severance and lease termination costs associated with care center closures and consolidations.
Personal Care Segment
The following table summarizes our personal care segment results of operations:

| For the Six-Month Periods Ended June 30,
| 2022 |  | 2021
Financial Information (in millions): |  |  |
Medicare | $ | — |  |  | $ | — |
Non-Medicare | 28.9 |  |  | 34.0 |
Net service revenue | 28.9 |  |  | 34.0 |
Other operating income | — |  |  | — |
Cost of service | 22.2 |  |  | 25.7 |
Gross margin | 6.7 |  |  | 8.3 |
Other operating expenses | 4.5 |  |  | 6.2 |
Depreciation and amortization | 0.1 |  |  | 0.1 |
Operating income | $ | 2.1 |  |  | $ | 2.0 |
Key Statistical Data - Total: |  |  |
Billable hours | 923,555 |  |  | 1,216,738 |
Clients served | 8,591 |  |  | 10,908 |
Shifts | 395,738 |  |  | 518,506 |
Revenue per hour | $ | 31.27 |  |  | $ | 27.96 |
Revenue per shift | $ | 72.99 |  |  | $ | 65.60 |
Hours per shift | 2.3 |  | 2.3

Operating Results
Operating income related to our personal care segment remained flat on a $5 million decrease in net service revenue. The decrease in net service revenue is due to the impact of COVID-19 and staffing shortages partially offset by rate increases. These impacts have been mitigated by a reduction in our cost of service as most of our personal care employees are paid on an hourly basis as well as a reduction in our other operating expenses.
42

High Acuity Care Segment
The following table summarizes our high acuity care segment results of operations:

| For the Six-Month Periods Ended June 30,
| 2022 |  | 2021
Financial Information (in millions): |  |  |
Medicare | $ | 1.7 |  |  | $ | — |
Non-Medicare | 5.5 |  |  | — |
Net service revenue | 7.2 |  |  | — |
Other operating income | — |  |  | — |
Cost of service | 7.0 |  |  | — |
Gross margin | 0.2 |  |  | — |
Other operating expenses | 15.9 |  |  | — |
Depreciation and amortization | 1.6 |  |  | — |
Operating loss | $ | (17.3) |  |  | $ | — |
Key Statistical Data - Total: |  |  |
Full risk admissions | 210 |  |  | — |
Limited risk admissions | 468 |  |  | — |
Total admissions | 678 |  |  | — |
Full risk revenue per episode | $ | 10,672 |  |  | $ | — |
Limited risk revenue per episode | $ | 5,541 |  |  | $ | — |
Number of admitting joint ventures | 9 |  |  | — |

Operating Results
Overall, our high acuity care segment generated revenue totaling $7 million and an operating loss of $17 million. Although we expect our high acuity care segment to continue to generate operating losses throughout the remainder of the year, we also expect improvement in our operating income as we leverage our operating structure through growth in current and future joint ventures and expansion into new lines of business such as palliative care at home.
Net Service Revenue
Our high acuity care segment provides home recovery care services for high acuity patients on either a full risk or limited risk basis, each with different reimbursement arrangements. Full risk admissions are admissions for which we assume the financial risk for all related healthcare services during a 30-day or 60-day episodic period in exchange for a fixed contracted bundled rate. Limited risk admissions are admissions for which we assume the risk for certain healthcare services during a shorter acute phase period (equivalent to an inpatient hospital stay) in exchange for a contracted per diem payment.
Additionally, on March 23, 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing joint ventures. As a result, our high acuity care segment includes revenue totaling approximately $2 million related to this joint venture's home health operations.
Cost of Service, Excluding Depreciation and Amortization
Our cost of service consists primarily of medical costs associated with direct clinician care provided to our patients during the applicable episode period, whether such care was provided on the day of program admission, in the patients’ homes or via telehealth, as well as costs associated with our virtual care unit (“VCU”), which enables us to provide monitoring services and facilitates virtual patient rounding visits via telehealth. We continue to invest in the infrastructure of our VCU in anticipation of future growth.
43

Other Operating Expenses
Other operating expenses primarily consist of salaries and benefits. We have made significant investments to build the clinical, operational and technological infrastructure necessary to support the development and future growth of home recovery care programs on a national scale. We have employees at both the local market level and at our corporate offices.
Corporate
The following table summarizes our corporate results of operations:

| For the Six-Month Periods Ended June 30,
| 2022 |  | 2021
Financial Information (in millions): |  |  |
Other operating expenses | $ | 77.9 |  |  | $ | 84.9 |
Depreciation and amortization | 8.8 |  |  | 10.7 |
Total operating expenses | $ | 86.7 |  |  | $ | 95.6 |

Corporate other operating expenses decreased approximately $7 million during the six-month period ended June 30, 2022 primarily due to higher gains on the sale of fleet vehicles, a favorable legal settlement and lower spend in various cost categories partially offset by higher acquisition and integration costs.
44

Liquidity and Capital Resources
Cash Flows
The following table summarizes our cash flows for the periods indicated (amounts in millions):

| For the Six-Month Periods Ended June 30,
| 2022 |  | 2021
Cash provided by operating activities | $ | 106.0 |  |  | $ | 122.0 |
Cash used in investing activities | (91.6) |  |  | (5.4) |
Cash used in financing activities | (11.4) |  |  | (107.3) |
Net increase in cash, cash equivalents and restricted cash | 3.0 |  |  | 9.3 |
Cash, cash equivalents and restricted cash at beginning of period | 45.8 |  |  | 83.3 |
Cash, cash equivalents and restricted cash at end of period | $ | 48.8 |  |  | $ | 92.6 |

Cash provided by operating activities decreased $16.0 million during the six-month period ended June 30, 2022 compared to the six-month period ended June 30, 2021 primarily due to a decrease in operating income and an increase in income tax payments partially offset by the timing of the payment of accrued expenses.
Our cash used in investing activities primarily consists of the purchase of property and equipment, investments and acquisitions. Cash used in investing activities increased $86.2 million during the six-month period ended June 30, 2022 compared to the six-month period ended June 30, 2021 as a result of our investment and acquisition activities.
Our financing activities primarily consist of borrowings under our term loan and/or revolving credit facility, repayments of borrowings, the remittance of taxes associated with shares withheld on non-cash compensation, proceeds related to the exercise of stock options, proceeds related to the purchase of stock under our employee stock purchase plan and our purchase of company stock under our stock repurchase program. Cash used in financing activities totaled $11.4 million during the six-month period ended June 30, 2022 primarily due to the remittance of taxes associated with shares withheld on non-cash compensation and the repurchase of company stock partially offset by net borrowings under our Revolving Credit Facility. Cash used in financing activities totaled $107.3 million during the six-month period ended June 30, 2021 due to the repurchase of company stock and net repayments of borrowings.
Liquidity
Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness.
During the six-month period ended June 30, 2022, we spent $2.8 million in capital expenditures as compared to $2.9 million during the six-month period ended June 30, 2021. Our capital expenditures for 2022 are expected to be approximately $6.0 million to $8.0 million, excluding the impact of any future acquisitions.
Additionally, during the six-month period ended June 30, 2022, pursuant to our authorized stock repurchase program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17 million. The repurchased shares are classified as treasury shares.
As of June 30, 2022, we had $26.6 million in cash and cash equivalents and $507.3 million in availability under our $550.0 million Revolving Credit Facility. We used cash on hand and proceeds from borrowings under our Revolving Credit Facility to fund the acquisitions of Evolution and AssistedCare on April 1, 2022 (see Note 4 – Acquisitions to our condensed consolidated financial statements for additional information).
Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements for the next twelve months and beyond.
45

Outstanding Patient Accounts Receivable
Our patient accounts receivable increased $30.4 million from December 31, 2021 primarily due to our acquisition activity and the shift from submitting Requests for Anticipated Payment ("RAPs") to Notice of Admissions ("NOAs") for reimbursement from Medicare. The intermediaries were delayed in accepting the NOAs and remitting payments. Our cash collection as a percentage of revenue was 104% and 103% for the six-month periods ended June 30, 2022 and 2021, respectively. Our days revenue outstanding at June 30, 2022 was 46.8 days, which is an increase of 3.6 days from December 31, 2021 and an increase of 4.1 days from June 30, 2021.
Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by acquisition activity, probe edits or regulatory changes which result in additional information or procedures needed prior to billing. The timely filing deadline for Medicare is one year from the date of the last billable service in the 30-day billing period and varies by state for Medicaid-reimbursable services and among insurance companies and other private payors.
The following schedules detail our patient accounts receivable, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding):

| 0-90 |  | 91-180 |  | 181-365 |  | Over 365 |  | Total
At June 30, 2022: |  |  |  |  |  |  |  |  |
Medicare patient accounts receivable | $ | 184.3 |  |  | $ | 19.5 |  |  | $ | 2.6 |  |  | $ | 1.8 |  |  | $ | 208.2 |
Other patient accounts receivable: |  |  |  |  |  |  |  |  |
Medicaid | 16.5 |  |  | 1.2 |  |  | 0.6 |  |  | — |  |  | 18.3 |
Private | 65.4 |  |  | 9.8 |  |  | 3.7 |  |  | — |  |  | 78.9 |
Total | $ | 81.9 |  |  | $ | 11.0 |  |  | $ | 4.3 |  |  | $ | — |  |  | $ | 97.2 |
Total patient accounts receivable |  |  |  |  |  |  |  |  | $ | 305.4 |
Days revenue outstanding (1) |  |  |  |  |  |  |  |  | 46.8 |
| 0-90 |  | 91-180 |  | 181-365 |  | Over 365 |  | Total
At December 31, 2021: |  |  |  |  |  |  |  |  |
Medicare patient accounts receivable | $ | 176.7 |  |  | $ | 7.5 |  |  | $ | 1.1 |  |  | $ | 1.4 |  |  | $ | 186.7 |
Other patient accounts receivable: |  |  |  |  |  |  |  |  |
Medicaid | 16.0 |  |  | 1.5 |  |  | 0.7 |  |  | — |  |  | 18.2 |
Private | 59.7 |  |  | 8.7 |  |  | 1.7 |  |  | — |  |  | 70.1 |
Total | $ | 75.7 |  |  | $ | 10.2 |  |  | $ | 2.4 |  |  | $ | — |  |  | $ | 88.3 |
Total patient accounts receivable |  |  |  |  |  |  |  |  | $ | 275.0 |
Days revenue outstanding (1) |  |  |  |  |  |  |  |  | 43.2 |

(1)Our calculation of days revenue outstanding is derived by dividing our ending patient accounts receivable at June 30, 2022 and December 31, 2021 by our average daily net service revenue for the three-month periods ended June 30, 2022 and December 31, 2021, respectively.
Indebtedness
Second Amendment to the Credit Agreement
On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0 billion, which includes a $550.0 million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0 million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").
Net proceeds from the $450.0 million Amended Term Loan Facility were used to fund the Contessa acquisition.
46

Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 2.9% for the three and six-month periods ended June 30, 2022, and 1.7% and 1.8% for the three and six-month periods ended June 30, 2021, respectively. Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 2.3% and 2.0% for the three and six-month periods ended June 30, 2022, respectively, and 1.4% and 1.5% for the three and six-month periods ended June 30, 2021, respectively.
As of June 30, 2022, our consolidated leverage ratio was 1.7, our consolidated interest coverage ratio was 15.4 and we are in compliance with our covenants under the Second Amended Credit Agreement.
As of June 30, 2022, our availability under our $550.0 million Revolving Credit Facility was $507.3 million as we have $15.0 million outstanding in borrowings and $27.7 million outstanding in letters of credit.
See Note 5 – Long Term Obligations to our condensed consolidated financial statements for additional details on our outstanding long-term obligations.
Stock Repurchase Program
On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we could repurchase up to $100 million of our outstanding common stock through December 31, 2021 (the "2021 Share Repurchase Program").
Under the terms of the 2021 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.
Pursuant to this program, we repurchased 4,757 shares of our common stock at a weighted average price of $249.72 per share and a total cost of approximately $1 million during the three-month period ended June 30, 2021 and 297,105 shares of our common stock at a weighted average price of $249.29 per share and a total cost of approximately $74 million during the six-month period ended June 30, 2021. The repurchased shares were classified as treasury shares. The 2021 Share Repurchase Program expired on December 31, 2021.
On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through December 31, 2022. This program commenced upon the completion of the Company's 2021 Share Repurchase Program (the "New Share Repurchase Program").
Under the terms of the New Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.
Pursuant to this program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17 million during the three and six-month periods ended June 30, 2022. The repurchased shares are classified as treasury shares.
Inflation
We do not believe inflation has significantly impacted our results of operations.
Critical Accounting Estimates
See Part II, Item 7 – Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our 2021 Annual Report on Form 10-K for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions or involve uncertainties. These critical accounting estimates include revenue recognition, business combinations and goodwill and other intangible assets. There have not been any changes to our significant accounting policies or their application since we filed our 2021 Annual Report on Form 10-K.
47

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to market risk from fluctuations in interest rates. Our Term Loan and Revolving Credit Facility carry a floating interest rate which is tied to the Eurodollar rate (i.e. LIBOR) and the Prime Rate, and therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows are exposed to changes in interest rates. As of June 30, 2022, the total amount of outstanding debt subject to interest rate fluctuations was $456.6 million. A 1.0% interest rate change would cause interest expense to change by approximately $4.6 million annually, assuming the Company makes no principal repayments.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized, disclosed and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.
In connection with the preparation of this Quarterly Report on Form 10-Q, as of June 30, 2022, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.
Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2022, the end of the period covered by this Quarterly Report.
Changes in Internal Controls
There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended June 30, 2022, that have materially impacted, or are reasonably likely to materially impact, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls’ effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2022, the end of the period covered by this Quarterly Report.
48

PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
See Note 6 – Commitments and Contingencies to the condensed consolidated financial statements for information concerning our legal proceedings.
ITEM 1A. RISK FACTORS
There have been no material changes in the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2021.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended June 30, 2022:

Period | (a) Total Number of Shares (or Units) Purchased |  | (b) Average Price Paid per Share (or Unit) |  | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs |  | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) That May Yet Be Purchased Under the Plans or Programs
April 1, 2022 to April 30, 2022 | 180 |  |  | $ | 135.85 |  |  | — |  |  | $ | 100,000,000 |
May 1, 2022 to May 31, 2022 | — |  |  | — |  |  | 150,000 |  |  | 82,648,900 |
June 1, 2022 to June 30, 2022 | 466 |  |  | 120.10 |  |  | — |  |  | 82,648,900 |
| 646 |  | (1) | $ | 124.49 |  |  | 150,000 |  |  | $ | 82,648,900 |

(1)Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding and/or strike price obligations in connection with the vesting of non-vested stock and exercise of stock options previously awarded to such employees under our 2008 and 2018 Omnibus Incentive Compensation Plans.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
None.
49

ITEM 6. EXHIBITS
The exhibits marked with the cross symbol (†) are filed and the exhibits marked with a double cross (††) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

Exhibit Number |  | Document Description |  | Report or Registration Statement |  | SEC File or Registration Number |  | Exhibit or Other Reference
3.1 |  | Composite of Certificate of Incorporation of the Company inclusive of all amendments through June 14, 2007 |  | The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 |  | 0-24260 |  | 3.1 |
3.2 |  | Composite of By-Laws of the Company inclusive of all amendments through October 20, 2021 |  | The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 |  | 0-24260 |  | 3.2 |
†31.1 |  | Certification of Christopher T. Gerard, President and Chief Executive Officer (principal executive officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |
†31.2 |  | Certification of Scott G. Ginn, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |
††32.1 |  | Certification of Christopher T. Gerard, President and Chief Executive Officer (principal executive officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |
††32.2 |  | Certification of Scott G. Ginn, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |
†101.INS |  | Inline XBRL Instance - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  |  |  |  |  |
†101.SCH |  | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  |  |
†101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  |  |
†101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase |  |  |  |  |  |
†101.LAB |  | Inline XBRL Taxonomy Extension Labels Linkbase Document |  |  |  |  |  |
†101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  |  |
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |  |  |  |  |  |

50

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

A MEDISYS, I NC. (Registrant)
By: |  | /s/ SCOTT G. GINN
|  | Scott G. Ginn,
|  | Principal Financial Officer and
|  | Duly Authorized Officer

Date: July 28, 2022
51